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Abstract  
Multi-Drug-Resistance (MDR) efflux pumps have been increasingly reported in 
Gram negative and Gram positive bacteria. These efflux mechanisms pump out a wide 
variety of structurally unrelated antimicrobials thus leading to reduced susceptibility due 
to lowered intracellular concentrations. The activity of such antimicrobials can be 
restored by the inhibition of the multi-drug efflux pumps. Several MDR pump inhibitors 
which inhibit the efflux mechanisms in bacteria have been identified. Reserpine and 
verapamil are two such inhibitors showing considerable effects on the MDR pumps. But 
the concentrations required to achieve these effects are too high to be clinically relevant. 
Reserpine has adverse effects such as neurotoxicity. The identification and development 
of safe and effective inhibitors of bacterial efflux pumps is needed. Crude leaf extracts of 
goldenseal (Hydrastis canadensis) have been shown to have such effects.  
This dissertation researches the MDR pump inhibitory activity of goldenseal leaf 
extract and the separation of its constituents. First, three forms of goldenseal samples 
supplied by the Sleepy Hollow Farm, GA were evaluated for their antimicrobial 
properties. Minimum inhibitory concentration (MIC) of all different forms of goldenseal 
i.e, powders, liquid extracts, and retention solids, in five different ratios of root/leaf 
combinations was determined against MDR bacterial strains of Staphylococcus aureus 
and Campylobacter jejuni. The antimicrobial activity of goldenseal samples was also 
determined against human intestinal beneficial bacteria, Lactobacillus acidophilus. 
Goldenseal liquid extracts were found to have high activity against the MDR bacteria 
while showing minimum impacts on the viability of L. acidophilus.  
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Second, goldenseal leaf extract was assayed for its MDR efflux pump inhibitory 
activity against MDR pumps belonging to different pump superfamilies in both S. aureus 
and C. jejuni. Goldenseal increased the potency of different antimicrobials against the 
MDR bacteria when combined in sub lethal doses (≤ 0.5MIC) by exerting at least a 2-fold 
reduction in MICs of antimicrobials against S. aureus strains and a 16-fold reduction 
against C. jejuni strain. Quantitative real-time RT-PCR and ethidium bromide 
uptake/efflux studies indicated that goldenseal leaf extract represses the genes encoding 
these MDR pumps in both bacterial systems. 
Finally, five active bands exhibiting potential MDR efflux pump inhibitory 
activity were identified in thin layer chromatography and bioautographic studies. The 
identity of these bands could not be established by GC/MS which might be due to the 
volatility of the compound. LC/MS analysis led to a list of possible compounds in these 
active bands. In conclusion, the results of this work indicate that one or more constituents 
in goldenseal leaf extract exhibit MDR efflux pump inhibitory activity. 
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Chapter 1 
Literature Review 
 
1.1 Antibiotic Resistance: 
Antibiotics are substances that kill bacteria or prevent their reproduction. Since 
their discovery in the 1940’s, use of antibiotics has led to possible treatment of many 
bacterial infections that once killed millions. Between 1940’s and 1970’s life expectancy 
rate increased by 8 years and, much of it has been attributed to antibiotics (Riley, 2001). 
Penicillin, the first introduced antibiotic discovered by Sir Alexander Fleming, was used 
to effectively treat Streptococcus pneumonia infections during the World War II. 
Resistance to antibiotics was observed in bacteria soon after their introduction as 
chemotherapeutic agents against bacterial infections. Antibiotic resistant bacteria are 
defined as the strains of bacteria that can grow and divide normally in the presence of an 
antibiotic that should kill or inhibit their growth. In 1967 the first penicillin-resistant S. 
pneumoniae was observed in Australia, and seven years later in USA, another case of 
penicillin-resistant S. pneumoniae was observed in a patient with pneumococcal 
meningitis (Doern, 2001). This trend was observed with other bacteria and antibiotics. 
Tetracycline resistance by normal human intestinal flora increased from 2% in the 1950s 
to 80% in the 1990s. Kanamycin, an antibiotic used in the 1950s, became clinically 
useless as a result of the prevalence of kanamycin-resistant bacteria (Shoemaker, 2001). 
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1.2 Mechanisms of Antibiotic Resistance: 
Bacteria develop resistance to antimicrobials by various mechanisms which 
include: change in metabolic pathways, (Hancock 1997, 1998), production of enzymes 
which inactivate the agents (Thomson and Smith, 2000), alteration of target sites 
(Hooper, 2000) and active efflux from cells (Poole, 2000). 
Many mechanisms with which bacteria utilize to defend themselves from 
antibiotics are depicted in Figure1.1. The four major mechanisms of antibiotic resistance 
are drug inactivation or modification, alteration of target site, metabolic pathway 
modification and efflux pumps. 
 Drug inactivation or modification by the production of antibiotic degrading 
enzymes is the best known mechanism. Examples for this are the β-lactamases which 
cleave the β-lactam ring in the penicillin rendering it inactive. Around 200 β-lactamases 
have been isolated and these are wide spread in most bacteria and show varying degrees 
of resistance to β-lactamase inhibitors, such as clavulanic acid (Livermore, 1995). 
Alteration of target site, which becomes resistant to inhibition by the antibiotic 
while continuing to produce the initial sensitive target, is the second mechanism. This 
allows bacteria to survive in the face of selection; the alternative enzyme “bypasses” the 
effect of the antibiotic. An example is the alternative penicillin binding protein (PBP2a), 
which is produced in addition to the normal penicillin binding proteins by methicillin 
resistant Staphylococcus aureus (MRSA). This protein is encoded by the mecA gene, and 
because PBP2a is not inhibited by antibiotics such as penicillin, the cell continues to 
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synthesize peptidoglycan and hence has a structurally sound cell wall (Michel, Gutmann, 
1997). 
 
 
Figure 1.1: Antibiotic resistance mechanism: (Hawkey, 1998) 
 
Metabolic pathway modification is another resistance mechanism which bacteria 
exhibit. Sulfonamides inhibit the enzyme dihydropterate synthetase of bacteria which acts 
upon para-aminobenzoic acid, a precursor of folic acid. This enzyme is not found in 
mammalian cells. This makes sulfonamides a better choice for treatment of bacterial 
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infections. Resistance is developed by the bacteria by their utilizing preformed folic acid 
like mammalian cells (Beneveniste, Davies, 1973). 
All living cells express multidrug efflux transporters as surface proteins which 
recognize a wide range of structurally dissimilar hydrophobic organic compounds and 
extrude them from the cytoplasm into the outer medium (Ambudkar, 1999, Putman, 
2000, Georgiev, 2000). Resistant bacteria overexpress such pumps or work in synergy 
with other factors (Jun Lin, 2003). Examples of such pumps are NorA in S. aureus and 
CmeABC in C. jejuni. Substrates for these pumps include various anti cancer and 
antimicrobial agents. 
1.3 Multi-Drug-Resistance Efflux Pumps: 
Multi-drug-resistance (MDR) is defined as the ability of bacteria to show 
resistance against structurally different compounds. A simple error in the DNA 
replication could lead to MDR. But such small mutations do not explain the rate at which 
the MDR spreads through generations, as the mutation occur at low frequencies and is 
due to a change on the chromosome. The rapid spread of MDR has been attributed to 
plasmid transfer (Kruse, 1996). 
Resistance due to MDR efflux pumps has been widely reported in the last two 
decades (Lewis, 1994, Nikaido, 1994), since P-glycoprotein was first identified by R. L. 
Juliano and V. Ling. Unlike other resistance genes which are either plasmid encoded or 
specific for a given antibiotic and which are acquired through horizontal gene transfer, 
the genes for efflux pumps are found in all living things. Efflux pumps prevent the 
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accumulation of antibiotics by pumping them out of the cell. These efflux pumps are 
modified transport proteins present on the cell membrane which form solute-specific 
channels or transport pathways (Nikaido, Saier Jr, 1992).  
The MDR pumps have been found to be homologous to regular, substrate-specific 
transporters. The MDR pumps Bmr, Blt and NorA of Gram positive bacteria share a 
higher sequence similarity with tetracycline transporters TetA, B and C of Gram negative 
bacteria than with other MDR pumps belonging to the same family. Hence it is evident 
that drastic changes in the transporter structure are not required for these MDR pumps to 
acquire the ability to recognize multiple compounds. This can be further proved by the 
fact that pumps of different families share similarity in substrates, for example a major 
facilitator Bmr and an ABC transporter P-glycoprotein recognize largely overlapping 
spectra of substrates and share many common inhibitors like reserpine (Neyfakh, 1991). 
Co-existence of multiple mechanisms of resistance to a particular antibiotic in a 
single bacterial cell has been demonstrated in several bacteria. A single cell may also 
contain more than one efflux pump capable of efflux of the same antibiotic. Escherichia 
coli or Pseudomonas aeruginosa despite the presence of endogenous MDR pumps 
(AcrAB-TolC and MexAB-OprM, respectively) in their genome may acquire plasmid-
encoded transporters such as TetA or CmlA through mutation, which can also transport 
tetracycline and chloramphenicol (Nikaido, 1998, Poole, 2000). P. aeruginosa contains 
multiple MDR pumps that can confer resistance to fluoroquinolones (Lomovskaya, 
2000). 
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1.4 Multi-Drug Efflux Pump Classification: 
MDR pumps are classified into five families: ATP binding cassette (ABC) 
(Lubelski, 2007), major facilitator super family (MFS) (Law, 2008), resistance nodulation 
cell division (RND) (Tseng, 1999), small multidrug resistance (SMR) (Chung & Saier, 
2001) and multidrug and toxic compound extrusion (MATE) (Moriyama, 2008). A 
characterization of these pumps is shown in Figure 1.2. All of these families are energy 
dependent active drug efflux transporters and utilize energy through either ATP or proton 
motive force (PMF) (Paulsen, 1998,). ABC transporters are dependent on ATP hydrolysis 
(primary active transporters), MFS, RND and SMR are proton-driven efflux pumps and 
MATE transporters consist of a Na+/H+ drug antiporter system (secondary active 
transporters). Examples of MDR efflux pumps in Gram positive and Gram negative 
bacteria are given in Figure 1.3. 
 
Figure 1.2: Representative members of the five characterized families of multidrug  
 efflux pumps (Paulsen, 2003) 
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1.5 Multi-Drug Efflux Pump Structure: 
Primary Active Transporters: 
Crystallization of the ABC proteins has proved difficult but electron microscopic 
studies of single particles and 2D crystals have provided low-resolution structural 
information. This structural information elucidates a hexagonal ring of protein with a 
central asymmetrical pore (Borges-Walmsley, McKeegan, 2003).  
 
                 
 
Figure 1.3: MDR pumps in Gram positive and Gram negative bacteria (Piddock, 2006) 
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Secondary Active Transporters: 
The structure of the secondary active transporters differs from one another. MFS 
transporters are typically composed of approximately 400 amino acids that are putatively 
arranged into 12 membrane-spanning helices, with a large cytoplasmic loop between 
helices six and seven (Saier, 1999). RND transporters are much larger than MFS 
transporters, being composed of approximately 1000 amino acid residues (Tseng, 2003). 
Unlike MFS transporters, they possess large periplasmic or extracytoplasmic domains 
between helices 1 and 2 and between helices 7 and 8 (Murakami, 2003). SMR 
transporters are much smaller than those belonging to the MFS and RND families. SMR 
pumps are normally composed of around 100 amino acids that are putatively arranged 
into four helices (Paulsen, 1996). MATE transporters are similar in size to the MFS 
transporters, and are typically composed of approximately 450 amino acids which are 
putatively arranged into 12 helices; however, they do not have any sequence similarity to 
members of the MFS transporters (Jack, 2001). 
Efflux pumps are differentiated based on the number of components they possess, 
which also determines the extrusion of antibiotics from the cell. Single component efflux 
pumps such as TetA extrude the antibiotic into the periplasmic membrane which results 
in maintaining a concentration gradient across the inner membrane (Thanassi, 1997). 
Two-component efflux pumps such as TolC, AcrA and AcrB, have a transporter which 
brings the two components together thus allowing extrusion of antibiotics into the 
external medium (Zgurskaya and Nikaido 1999a; Zgurskaya and Nikaido, 1999b). This 
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results in a concentration gradient across the outer membrane and decreases in antibiotic 
levels in the periplasmic membrane. 
Over expression of these MDR pumps has led to the development of drug 
resistant tumor and bacterial and fungal infections. Inhibition of these pumps can lead to 
increased drug sensitivity and provides a new approach to overcome multidrug resistance. 
Due to emergence of resistance to all classes of antibiotics, in particular the 
fluoroquinolones, significant interest has been shown on MDR pump inhibitors.  
One approach of overcoming resistance by MDR efflux pumps is the 
development of derivatives of existing antibiotics which are minimally affected by the 
efflux pumps. Examples of this are the glycylcyclines (Sum, 1998), a new class of semi-
synthetic tetracyclines which overcome MDR efflux pumps. The glycylcyclines are not 
recognized by the transporter proteins (Someya, 1995).  
1.6 Efflux Pump Inhibitors: 
Another approach for overcoming resistance due to MDR efflux pumps is the 
inhibition of these MDR efflux pumps by Efflux Pump Inhibitors (EPIs). In the present 
market there are no EPIs that can be used in combination with a drug that is a pump 
substrate to increase its activity. The concept of using a compound that inhibits resistance 
together with a conventional antibiotic is well proven (Esposito, Noviello, 1990). Several 
MDR pump inhibitors which inhibit the efflux mechanisms have been identified. Several 
factors such as appropriate potency and spectrum of activity, bioavailability, clearance, 
avoidance of mechanism-based and/or non-mechanism based toxicity need to be 
10 
 
considered when developing a new infectious disease drug. Development of an EPI will 
most obviously result in a combination therapy. 
In the selection of an effective EPI, several criteria should be considered: 
• Determining the selectivity of the EPI should be the foremost criteria to be 
ascertained. As mentioned earlier five families of MDR pumps have been 
identified and representatives of each family are present in both eukaryotic and 
prokaryotic cells and an EPI which would not be selective to specific pumps is 
best desired. 
• MDR efflux pumps though belonging to different families extrude similar 
antibiotics; hence it maybe possible to identify a single EPI which would target 
several relevant transporters. 
• MDR efflux pumps extrude structurally dissimilar compounds, so a random 
screening process is a more practical approach in initial designing of an EPI. 
 
MDR efflux pump inhibition by several synthetic chemical compounds has been 
demonstrated by various investigators. A library of 9600 synthetic molecules was 
screened against NorA pump yielded in about 4% of the coumpounds showing activity 
(Markham, 1999). All the coumpounds showed a 4-fold decrease in the MIC of 
ciprofloxacin in strains of S. aureus over expressing the NorA pump. Another synthetic 
compound MC-207 screened from a library of 200,000 synthetic compounds decreased 
the intrinsic resistance to levofloxacin, an. 8-fold, in a wild type strain of P. aeruginosa, 
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while in strains over-expressing efflux pumps the susceptibility was increased up to 64-
fold (Lomovskaya, 2001). 
Screening of 85,000 Streptomyces fermentations has resulted in the 
characterization of two new natural product EPIs, EA-371a and EA-371d (Lee,  2001). 
Both compounds caused a 4-fold reduction in the MIC of levofloxacin effluxed by the 
MexAB-OprM pump in P. aeruginosa. 
1.7 Plants as sources for EPIs: 
Reserpine is an antihypertensive plant alkaloid isolated from the roots of 
Rauwolfia vomitoria Afz (Poisson, 1954). Reserpine has been demonstrated to show 
activity against the Bmr efflux pump; this pump mediates tetracycline efflux in Bacillus 
subtilis (Neyfakh, 1991). 5′-methoxyhydnocarpin, isolated from Berberis fremontii, 
decreases the antimicrobial actvity of ciprofloxacin on NorA expressing strains of S. 
aureus (Sterimitz, 2000). 
There are many reasons for searching the plant world for possible EPIs; a few of 
them are listed below: 
• Soil is rich in microflora with bacteria, fungi and viruses, so it is rational to 
assume that plants produce several antimicrobials as part of their defense. Several 
bacterial species found in the soil are taxonomically similar to pathogenic 
bacteria; hence this relation could be further explored. 
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• 25% of prescription drugs and 60% of anticancer and antibiotics owe their origin 
directly or indirectly to natural products (Gibbons, 2008). This makes 
phytochemicals as natural products highly valuable as bioactive compounds. 
• Due to their difference in structures from microbial derivatives, phytochemicals 
might show a different mode of action distinct from the existing antibiotics. 
• There are several instances in history where plants have been used to treat varied 
ailments, Echinacea, St. John’s Wort, Ginseng etc, are a few examples. 
 
1.8 Hydrastis canadensis: 
Goldenseal (Hydrastis canadensis) (Figure1.4) belongs to the family 
Ranunculaceae. It is a small hairy perennial which emerges in early spring (mid-March to 
early May) and dies back in mid-August to mid-September. The natural range of the plant 
extends from southern New England west through the extreme southwestern portion of 
southern Ontario, to southern Wisconsin, and south to Arkansas and northern Georgia 
(Figure 1.5) (USDA page for plant profile). 
 
 
Figure 1.4: Hydrastine Canadensis (Goldenseal) 
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Historically, Native Americans have used goldenseal for various health conditions 
including skin diseases, ulcers, and gonorrhea. Its roots and rhizomes, which internally 
are bright yellow in color, have been used as a traditional medicine for the treatment of 
infection, inflammation, and as an immune system booster (Edwards, Draper, 2003).  
More recently it is known to be taken orally to treat upper respiratory infections 
and gastrointestinal tract disorders, and is commonly found in commercial products in 
combination with Echinacea purpurea (Borchers, 2000, Scazzocchio, 1998, Schieffer, 
2002). Modern herbalists consider it an alternative anti-catarrhal, anti-inflammatory, 
antiseptic, astringent, bitter tonic, laxative, and muscular stimulant (Grieve, 1971, Mills, 
2000, Birdall, 1997). Goldenseal has also been evaluated for its activity against MDR 
Mycobacterium tuberculosis (Gentry 1998). An increase in the primary IgM response 
was noticed in rats injected with the antigen keyhole limpet hemocyanin, on 
administration of goldenseal root powder (Maisel, 1999). It has been demonstrated as 
natural LDL-lowering agent (Abidi, 2006).  
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Figure 1.5: Distribution of Hydrastis canadensis (USDA, Plant Profile 2009) 
 
1.9 Chemical composition of Goldenseal: 
The National Toxicology Program is currently investigating the toxicology of 
goldenseal root powder. A rapid ambient extraction method to assay goldenseal root 
powder and determine its purity has been developed (Weber, 2003). The main 
components of goldenseal are its alkaloids: berberine, hydrastine and canadine (Figure 
1.6). It also possesses secondary metabolites such as protoanemonin and glycosides. 
Berberastine, meconin, chlorogenic acid, phytosterins, resins, albumin, starch, sugars, 
lignin, and volatile oil (in the root) are other compounds found in addition in goldenseal 
(Van Berkel, 2007). 
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Figure 1.6: Structures of alkaloids present in goldenseal, (a) berberine, (b) canadine and 
(c) hydrastine 
 
Berberine extracts and salts have been demonstrated to inhibit intestinal parasites 
like Giardia lamblia, Entamoeba histolytica, Trichomonas vaginalis, (Kaneda. Y 1990) 
and Leishmania donovani (Abidi, 2005). Crude extracts were more effective than 
berberine salts (Kong, 2004). Berberine provides the yellow color to the root and 
rhizome, hence the name “Yellow Root” for goldenseal. 
The other major alkaloid components are canadine and hydrastine. Canadine is 
known for its sedative and muscle relaxant properties. Hydrastine is a valuable drug in 
the treatment of diseases of the skin. Both of them are taken internally into the body or as 
a topical application. Hydrastine is especially useful as a stomachic tonic, and as a 
hepatic stimulant in cutaneous infections. Better activity is exhibited when hydrastine is 
used as a topical application than taken internally (Beckstrom-Sternberg, 1997).  
Two new C-methyl flavonoids, 6, 8-di- C-methylluteolin 7-methyl ether and 6- C-
methylluteolin 7-methyl ether have been isolated and these show activity against oral 
a b 
c 
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pathogens such as Streptococcus mutans and Fusobacterium nucleatum (Hwang, 2003). 
Quinic acid feruloyl esters have also been identified and their activities against 
Mycobacterium tuberculosis have been evaluated, but have been shown not to have a 
significant effect (Gentry, 1999). 
1.10 Objectives 
 The long term goal of this project is to develop therapies combining antimicrobial 
agents and MDR inhibitors to enhance the activities of antimicrobial agents, reduce the 
side effects associated with the use of antibiotics, and minimize the emergence of MDR 
pathogens. The main objectives of this project are: 
1. Determine the antimicrobial activity of different forms of goldenseal on 
Staphylococcus aureus and its effect on beneficial bacteria 
2. Determine the efflux pump inhibitory activity of goldenseal leaf extract on 
different families of efflux pumps in Gram negative and Gram positive bacteria 
3. Separation and identification of goldenseal leaf extract constituents 
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Chapter 2 
 
 
Antimicrobial Activity of Hydrastis canadensis (Goldenseal) 
 
2.1 Introduction 
Initially available only in specialty health and natural foods stores, goldenseal 
became part of the general marketplace during the 1990s, and since then the demand has 
been increased dramatically (Foster, 2000). Between 1991 and 1996, the wholesale value 
of goldenseal in the U.S. increased by as much as 600% (Robbins, 1996). Since 1994 
goldenseal has been one of the top six best-selling medicinal herbs in the U.S. (Robbins, 
1996; Small and Catling, 1999), and remains so today (Foster, 2000). Between 1995 and 
1997, the medicinal plant market as a whole, as well as demand for goldenseal, 
experienced in excess of a 30% growth rate (USFWS, 1997). Goldenseal is also available 
in numerous drug products (Small and Catling, 1999) and in a wide array of herbal 
products on international markets, e.g., in China, France, Australia, Germany, United 
Kingdom, Italy, and other European countries (IUCN, 1997; Robbins, 1996). Since 
demand has increased greatly, and supplies have declined, the price of goldenseal has 
increased dramatically.  
Presently, the quality of the goldenseal samples in the market is analyzed by 
methods developed by two groups: Genest and Hughes and those described by Wagner 
and Bladt (Govindan, 2000). But these methods check for adulteration and for the 
presence or absence of berberine. To develop research grade goldenseal, a more thorough 
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analysis, which involves testing of the sample goldenseal on different pathogens and 
beneficial bacteria, is required. 
The goldenseal samples for this work were supplied by the Sleepy Hollow Farm 
in Georgia. A brief description of the samples provided is given in Table 2.1. 
 
Table 2.1: List of samples provided by Sleepy Hollow Farm 
 
Sample Description Components 
Liquid Extracts 60% grain alcohol extracts. Supplied in  
different ratios and combinations 
Root and rhizome
Leaf and Stem 
Powders Dried, ground powder.  Supplied in different 
ratios and combinations 
Root and rhizome
Leaf and stem 
Retention Solids Solids obtained from retention of the liquid  
extracts by evaporation. 
Root and rhizome
Leaf and stem 
 
 
 
The primary objective of this study was to determine the antimicrobial 
characteristics of the various goldenseal preparations on MDR S. aureus, C. jejuni strains 
and beneficial bacteria existing as a normal gut flora of the human body such as 
Lactobacillsc acidophilus.  
 
2.2 Materials and Methods 
2.2.1 Bacterial Strains: 
The MDR strains selected for these studies were the NorA MDR pump over 
expresser strain: SA1199B and its wild type counterpart SA1199 donated by Dr. Glenn 
Kaatz. Lactobacillus acidophilus (ATCC 53544) strain was obtained from American 
Type Culture Collection. S. aureus strains were maintained in Mueller Hinton II (BD-
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Difco) medium at 35°C under aerobic conditions. L. acidophilus 53544 was maintained 
in MRS medium (BD-Difco) at 37°C with 5% CO2. 
2.2.2 Goldenseal Samples: 
The goldenseal samples were provided by the Sleepy Hollow Farm, GA as listed 
in Table 2.1. The liquid extracts and retention solids were lyophilized to determine the 
dry weight. 
2.2.3 Antimicrobial Assay: 
The Minimum inhibitory concentration (MIC) of the liquid extract and powder 
samples of goldenseal was determined by using the microbroth assay as described by the 
Clinical and Laboratory Standards Institute (CLSI). The antimicrobial is added in two-
fold dilutions in triplicates to round bottomed 96 well plate and each well is seeded with 
105 cell/ml in MH II broth (final volume in each well is 200µL). The plates are incubated 
aerobically at 35°C for 18-24hrs and observed for visual growth. MIC is determined as 
the lowest concentration of the antimicrobial with no visible growth.  The assays were 
performed twice in triplicates. 
Due to nature of the powder samples which would not make it possible to observe 
the growth in the wells of the 96 well plate, macrobroth technique is applied. The 
samples of goldenseal and bacteria were scaled up to a volume of 5mL. The tubes were 
incubated in a shaker incubator at 35°C for 18-24hrs under aerobic conditions. The tubes 
were taken out of the incubator and observed for turbidity after allowing the powders to 
settle. 
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Minimum bactericidal concentration (MBC) was determined by taking the 
inoculums (100µL) from the wells in the microbroth assay and resuspending in fresh 
liquid and solid MH II medium. The agar and broth was incubated aerobically at 35°C for 
18-24hrs and observed for growth. MBC is defined as the lowest concentration which 
would not give rise to any growth. All assays were performed twice in triplicates. For all 
the assays berberine sulfate was used as standard for comparison. 
 
2.3 Results 
The MIC and MBC of the goldenseal samples and berberine sulfate are displayed 
in Table 2.2. Among the three different combinations, liquid extracts yielded the best 
results. The liquid samples are achieved by the extraction of the root or stem of 
goldenseal in 60% grain alcohol at the Sleepy Hollow farm. Of the different preparations 
of the liquid extracts (mixtures consisting of different root/leaf ratio combinations); the 
2:2 R/L preparations has shown the maximum effect on the MDR S. aureus: SA1199B.  
The powders had a very high MIC values against the S. aureus strains, which was 
expected as the samples had more solid material than the others. The retention solids had 
comparatively moderate effect on the bacteria. But retention solids were supplied as thick 
paste of root or leaf, which when diluted to make the different ratios formed suspensions. 
The suspensions had to be shaken vigorously each time sample had to be taken, thus 
leading to the contributable inconsistency in the amount taken.  
The MBCs of the powder samples were twice the MIC values and there is no 
difference in the MIC and MBC of the retention solids. The MBCs of the liquid extracts 
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are slightly different than their MIC. The MIC and MBC of the extracts on the over 
expresser SA1199B are the same as the MICs. The MBC of the 4:0, 3:1 and 0:4 R/L 
preparations on the wild type SA1199 are the same, while the MBC of 2:2 and 1:3 R/L 
preparations are twice that of MIC. 
The MIC of goldenseal samples on L. acidophilus 53544 was much higher in 
comparison the MIC to that on the S.aureus. The MIC of different liquid extract 
prparations on L. acidophilus was greater than 2mg/mL, that of powder samples greater 
than 10mg/mL and that of retention solids greater than 2mg/mL.  
 
Table 2.2: MIC and MBC of all goldenseal samples on S. aureus SA1199 and SA1199B 
and L. acidophilus 
 
Goldenseal sample SA1199 SA1199B L. acidophilus 
Root/Leaf MIC MBC MIC MBC MIC MBC 
Powders 
4:0 5mg/mL  10mg/mL  5mg/mL  10mg/mL   
>5mg/ml 3:1 5mg/mL  10mg/mL  5mg/mL  10mg/mL  
2:2 5mg/mL  10mg/mL  5mg/mL  10mg/mL  
1:3 5mg/mL  10mg/mL  5mg/mL  10mg/mL  
0:4 5mg/mL  10mg/mL  5mg/mL  10mg/mL  
Liquid Extracts 
4:0 250µg/mL  250µg/mL  500µg/mL  500µg/mL   
>2000µg/mL 3:1 250µg/mL  250µg/mL  500µg/mL  500µg/mL  
2:2 250µg/mL  500µg/mL  500µg/mL  500µg/mL  
1:3 500µg/mL  1000µg/mL 1000µg/mL  1000µg/mL  
0:4 1000µg/mL  1000µg/mL 1000µg/mL  1000µg/mL  
Retention solids 
4:0 625 µg/mL  625 µg/mL  625 µg/mL  625 µg/mL   
>2000µg/mL 3:1 625 µg/mL  625 µg/mL  1250 µg/mL 1250 µg/mL  
2:2 1250µg/mL  1250µg/mL 1250µg/mL  1250 µg/mL  
1:3 1250µg/mL  1250µg/mL 1250µg/mL  1250 µg/mL  
0:4 1250µg/mL  1250µg/mL 1250µg/mL  1250 µg/mL  
Berberine sulfate 125µg/mL 125µg/mL 250µg/mL 250µg/mL 250µg/mL 
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The goldenseal samples were analyzed by the Sleepy Hollow Farm for the 
percentage of different constituents in them. Table 2.3 shows an interpretive of all the 
constituents in the liquid extracts. 
 
Table 2.3: Percentage of berberine and hydrastine in the goldenseal liquid extracts 
 
R/L Ratio Berberine 
mg/ml 
Hydrastine
mg/ml 
Percentage of 
Grain alcohol 
Dry Weight
mg/ml 
Berberine 
% 
Hydrastine
% 
4:0 1.53 1.11 53.00 8 mg/ml 19.13 13.875 
3:1 1.32 1.03 54.50 10 mg/ml 13.20 10.3 
2:2 1.1 0.95 56.00 10 mg/ml 11.00 9.50 
1:3 0.89 0.87 57.50 11 mg/ml 8.09 7.91 
0:4 0.67 0.79 59.00 13 mg/ml 5.15 6.08 
 
The MIC of berberine sulfate on the NorA over expresser strains SA1199B and L. 
acidophilus is 250µg/mL. Using the interpretive Table 2.3 the concentration of each 
liquid extract sample was calculated (Table 2.4). When the 2:2 R/L liquid extract 
preparation is taken into consideration, the MIC of this sample showed best antimicrobial 
activity on SA1199B (500µg/mL). The berberine content in this sample was calculated to 
be about 55µg/mL, almost one fifth of the MIC of pure berberine sulfate. This 
observation leads to the speculation that an unknown component(s) in the extract acts in 
synergy with berberine thus lowering its MIC. 
When tested against SA1199B, of all the liquid extracts tested the lowest 
concentration of berberine was determined to be in the leaf extract (0:4 R/L) preparation. 
This berberine level (51.50µg/mL) is much lower than the berberine level in the root 
extract (95.65µg/mL). This indicates that the highest activity (if present) of the unknown 
component is present in the leaf extract. 
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Table 2.4: MIC of goldenseal liquid extracts on different bacterial strains (the amount of    
equivalent berberine in each sample is given in the parenthesis  
 
R/L Ratio SA1199 (wild-
type) 
SA1199B (MDR) C.jejuni  
81-176 
L. acidophilus  
53544 
4:0 250 µg/ml 
(= 47.83µg/ml 
berberine) 
500 µg/ml 
(= 95.65µg/ml 
berberine) 
31.25 µg/ml 
(=5.98µg/mL 
beberine) 
> 2 mg/ml 
(> 382.60 µg/ml 
berberine) 
3:1 250 µg/ml 
(= 33.00 µg/ml 
berberine) 
500 µg/ml 
(= 66.00 µg/ml 
berberine) 
31.25 µg/ml 
(=4.125µg/mL 
beberine) 
> 2 mg/ml 
(> 264.00 µg/ml 
berberine) 
2:2 250 µg/ml 
(= 27.50 µg/ml 
berberine) 
500 µg/ml 
(= 55.00 µg/ml 
berberine) 
31.25 µg/ml 
(=3.44µg/mL 
beberine) 
> 2 mg/ml 
(> 220.00 µg/ml 
berberine) 
1:3 500 µg/ml 
(= 40.45 µg/ml 
berberine) 
1000 µg/ml 
(= 80.90 µg/ml 
berberine) 
62.5 µg/ml 
(=5.05µg/mL 
beberine) 
> 2 mg/ml 
(> 161.8 µg/ml 
berberine) 
0:4 1000 µg/ml 
(= 51.50 µg/ml 
berberine) 
1000 µg/ml 
(= 51.50 µg/ml 
berberine) 
62.5 µg/ml 
(=3.2µg/mL 
beberine) 
> 2 mg/ml 
(> 103 µg/ml 
berberine) 
Berberine 
sulfate 
125µg/mL 250µg/mL 8µg/mL 250µg/mL 
 
 
 
2.4 Discussion 
 
The results of the antimicrobial assay clearly indicate that the liquid extracts are 
much more effective on the S. aureus than the other forms of goldenseal. This might be 
due the fact that the grain alcohol has extracted the components responsible for the 
antimicrobial activity. Hence the liquid extracts are best form that can be projected for 
antimicrobial effect. The hisher antimicrobial activity of goldenseal leaf extract on L. 
acidophilus clearly indicates that the human beneficial strain was less susceptible to the 
antimicrobial activity of goldenseal than the S. aureus strains. This finding is favorable 
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since if goldenseal is administered as antimicrobial agent, the minimal the impact on the 
normal microflora is desirable. 
When tested against SA1199B, of all the liquid extracts tested the lowest 
concentration of berberine was determined to be in the leaf extract (0:4 R/L) preparation. 
This berberine level (51.50µg/mL) is much lower than the berberine level in the root 
extract (95.65µg/mL). This indicates that the highest activity (if present) of the unknown 
component is present in the leaf extract. The other alkaloids in the extracts, hydrastine 
and canadine have not been reported to have much antimicrobial activity. Hence it is safe 
to assume that berberine is responsible for the antimicrobial activity of goldenseal 
extracts 
The SA1199B strain used for this study, over expresses the NorA MDR efflux 
pump (Kaatz, 1991). The natural substrates for NorA pump include berberine, 
ciprofloxacin and ethidium bromide. Similarly the CmeABC pump in C. jejuni extrudes 
the antimicrobials like ciprofloxacin and ethidium bromide. Goldenseal leaf extract has 
exhibited antimicrobial property against these strains which when compared to the 
equivalent concentration of berberine in it, is much lower. The leaf extract as discussed 
earlier might consist of unknown component(s) that lower(s) the MIC of berberine in 
synergy and could be used as a potential MDR EPI.   
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Chapter 3 
 
Effect of Goldenseal Leaf Extract on MDR Pumps in Staphylococcus 
aurous and Campylobacter jejuni 
 
3.1 Introduction 
3.1.1 Staphylococcus aureus 
Species of the genus Staphylococcus cause a range of suppurative (pus-forming) 
diseases in humans and other animals. Staphylococci are Gram positive cocci and are 
characteristically nonmotile, catalase positive facultative anaerobes that grow in grape-
like clusters. The genera are also divided into coagulase positive and coagulase negative 
based on whether the bacteria can produce the enzyme coagulase, which clots the 
fibrinogen in blood. Staphylococcus aureus, the most invasive species, is coagulase 
positive and often produces a yellow carotenoid pigment, hence the name 'golden staph'. 
S. aureus causes acute to chronic infections, such as boils, deep tissue abscesses, 
enterocolitis, bacteriuria, osteomyelitis, pneumonia, carditis, meningitis, septicemia and 
arthritis. Coagulase negative species, such as Staphylococcus epidermidis, are 
opportunistic pathogens that although generally less invasive, are increasingly associated 
with serious infections (Von Eiff, 2002).  
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3.1.2 Methicillin Resistant S. aureus (MRSA): 
S. aureus was first proposed to be a major cause of wound suppuration by Sir 
Alexander Ogston (Ogston,1883) and Skinner and Keefer reported in 1941 that the 
mortality rate associated with S. aureus bacteremia in 122 patients at the Boston City 
Hospital was 82% (Skinner, Keefer, 1941). The discovery of penicillin by Sir Alexander 
Fleming led to the management of S. aureus infections but incidence of penicillin 
resistant S. aureus (PRSA) started emerging in the mid 1940’s. Introduction of 
methicillin in 1959 resulted in a general decline of pandemic phage-type 80/81 S. aureus, 
the strain responsible for the infections in hospitals and community. In two years, 
however, methicillin resistant S. aureus (MRSA) was isolated (Jevons, 1964) and, slowly, 
reports of small clusters started appearing. A general timeline of the emergence of 
resistant S. aureus is given in Figure 3.1. 
 
 
Figure 3.1: Timeline in years of emergence of antibiotic-resistant S. aureus, epidemic, 
and estimated deaths caused by MRSA in the United States. Arrows indicate 
approximate length of time for each pandemic/epidemic. (DeLeo, 2009) 
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In the United States, the numbers of hospitalizations due to S. aureus are 292,000 
of which 40% are caused by MRSA (Kuehnert, 2005). These infections have now been 
given the status of the number one cause of hospital acquired (HA MRSA) infections 
(DeLeo, 2009). Between the late 1970s and early 1980s and continuing to present day, 
there has been a growing incidence of hospital-associated (nosocomial) and also 
community-acquired (CA MRSA) infections caused by strains of S. aureus (Slade, 2009). 
MRSA infections in USA intensive-care units rose from 2% in 1974, to 22% in 1995 and 
64% in 2004 (Klevens, 2006). Community acquired infections were initially caused by 
methicillin sensitive S. aureus (MSSA), but CA MRSA fast emerged and it now occurs 
worldwide (Chambers, 2001). 
3.1.3 Pathogenesis of S. aureus: 
Those infections or syndromes caused by S. aureus are listed in Tables 3.1. There are five 
stages in the pathogenesis of S. aureus infections: colonization, local infection, systemic 
dissemination and/or sepsis, metastatic infection, and toxinosis. Approximately 30% of 
humans are asymptomatic nasal carriers of S. aureus (Archer, 1998) carrying it in their 
anterior nares, such that in these individuals S. aureus is part of the normal flora. S. 
aureus carriers are at higher risk of infection and are presumed to be an important source 
of the S. aureus strains that spread among individuals. The primary mode of transmission 
of S. aureus is by direct contact, usually skin-to-skin contact with a colonized or infected 
individual, although contact with contaminated objects and surfaces might also have a 
role. Local abscesses of skin or skin structures result when the organism is inoculated 
into the skin from a site of carriage. The infection can spread locally (e.g., carbuncle, 
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cellulites, impetigo bullosa, or wound infection) or can gain access to the blood and cause 
bacteremia. 
 
    Table 3.1: Primary and secondary infections caused by S. aureus 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.4 Multi-Drug-Resistance in S. aureus: 
MRSA are not only resistant to methicillin, but maybe resistant to as many as 20 
different antimicrobial compounds, including various biocides, representing most of the 
available drug classes (Table 3.2). According to most surveys (Archer, 1991, Truckiss, 
1991), 50% of MRSA are also resistant to macrolides, lincosamides, fluoroquinolones, 
and amino glycosides. The threat posed by such antibiotic-resistant pathogens to patient 
health and to the community in general has initiated considerable research into the nature 
of the genes encoding antibiotic resistance and the mechanisms by which these genes 
spread and evolve in bacterial populations. 
Primary symptoms Secondary symptoms 
Furuncle or carbuncle Cellulites 
Impetigo bullosa Hospital-acquired bacteremia 
Surgical wound infection  Hematogenous osteomyelitis 
Pyomyositis  Septic arthritis  
Botryomycosis  Brain abscess 
Acute or right-sided endocarditis Hospital-acquired pneumonia 
Epidural abscess  Emphysema 
Toxic shock syndrome  Septic shock 
Scalded skin syndrome Food-borne gastroenteritis 
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Goldenseal leaf extract exhibited effective antimicrobial activity on the NorA 
pump carrying strain of S. aureus and CmeABC pump carrying strain of C. jejuni. For the 
further analysis, three more different MDR pumps isolated from S. aureus were chosen 
and a brief description of each is given below: 
NorA Efflux Pump: 
The NorA MDR efflux extrudes various structurally distinct compounds such as: 
berberine, ciprofloxacin and ethidium bromide. It is mainly responsible for 
fluoroquinolone resistance in S. aureus (Nikaido, 2009). The gene for this pump, norA is 
present on the chromosome (Yoshida, 1990) and the MDR strains over express the gene 
norA in comparison to the wild type strain. NorA belongs to the major facilitator super 
family (MFS) of pumps and has 12 transmembrane segments (Paulsen, 1996). The NorA 
show structural homology to the Bacillus subtilis Bmr and Blt pumps and NorA mediated 
drug transport like that of Bmr is reserpine sensitive (Kaatz, 1993). 
MepA Efflux Pump: 
MepA is the first S. aureus MATE family MDR transporter to be identified and is 
capable of transporting several clinically relevant biocides and antimicrobial agents. It is 
repressed by the product of mepR, which is present on the same gene cluster as mepA in, 
the mepRAB cluster (Kaatz, 2006). The gene cluster is present on the chromosome, while 
in the wild type only the mepR is seen, in the over expressers, the whole mepRAB cluster 
is seen. Like the NorA pump the MepA MATE pump is sensitive to reserpine. 
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Table 3.2: Examples of Antimicrobial Resistance Determinants in S. aureus (Slade,   
                 2006) 
 
Antimicrobial agent Resistance determinant Mechanism of resistance 
Biocides qacA, B, C Multidrug efflux pump (MFS) 
Bleomycin ble Bleomycin binding protein 
Chloramphenicol cat Chloramphenicol acetyltransferase 
Chloramphenicol, 
lincosamides, linezolid 
cfr 23S rRNA methyltransferase 
Fluoroquinolones grlA/B DNA topoisomerase IV 
Fluoroquinolones gyrA/B DNA gyrase 
Fluoroquinolone  norA Multidrug efflux pump (MFS) 
Fusidic acid fusA EF-G (elongation factor) 
Fusidic acid fusB Fusidic acid detoxification 
Gentamicin, kanamycin aacA-aphD 6′-aminoglycoside N-acetyltransferase/2″-
aminoglycoside phosphotransferase 
Linezolid 23S rRNA genes 23S rRNA 
Methicillin, oxacillin mecA PBP2a (low-affinity PBP) 
MLS group erm(A) rRNA adenine N-6-methyltransferase 
MLS group erm(B) rRNA adenine N-6-methyltransferase 
MLS group erm(C) rRNA adenine N-6-methyltransferase 
Streptogramin A vga(A)(B) MLS efflux pump (ABC) 
Streptogramin A vat(A)(B) Virginiamycin A acetyltransferase 
PStreptogramin B vgb(A) Streptogramin B lyase 
Mupirocin ileS Isoleucyl tRNA synthetase 
Mupirocin ileS-2 Insensitive isoleucyl tRNA synthetase 
Neomycin, kanamycin aphA-3 Aminoglycoside phosphotransferase 
Neomycin, kanamycin aadD Aminoglycoside adenyltransferase 
Penicillin blaZ Class A b-lactamase 
Penicillin mecA PBP2a (low-affinity PBP) 
Rifampicin rpoB RNA polymerase b-subunit 
Spectinomycin spc Spectinomycin adenyltransferase 
Streptomycin str Streptomycin adenyltransferase 
Streptomycin aadE Streptomycin adenylyltransferase 
Streptothricin sat4 Streptothricin acetyltransferase 
Tetracycline tetA(K) Tetracycline efflux pump (MFS) 
Tetracycline tetA(L) Tetracycline efflux pump (MFS) 
Tetracycline, minocycline tetA(M) Ribosomal protection protein 
Tigecycline mepA Multidrug efflux pump (MATE) 
Trimethoprim dfrA Insensitive dihydrofolate reductase 
Trimethoprim dfrB Insensitive dihydrofolate reductase 
Vancomycin, teicoplanin vanHAXYZ Glycopeptide resistance 
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MsrA Efflux Pump: 
The MsrA pump extrudes macrolides and has been isolated from various strains 
of S. aureus. It belongs to the RND MDR pump family. No known EPIs of the MsrA 
have been reported until recently, diterpine totaral was recently shown to have inhibitory 
activity against this pump (Kaatz, 2007). 
3.1.5 Campylobacter jejuni 
Campylobacter jejuni is one of the leading causes of gastroenteritis in humans in 
USA and worldwide (Wesley, 2000). Instances of infections due to Campylobacter date 
back to 1886, when Escherich observed campylobacters in the stools of children with 
diarrhea (Kist, 1985). These were determined to be the cause of diarrhea in 1956 but were 
thought to be Vibrio (King, 1957). The genus Campylobacter was proposed in 1973 
(Vernon, 1973) and by 1980s Campylobacter was identified to be the leading cause of 
bacterial gastroenteritis by worldwide (Allos, 2001). C. jejuni is a microaerophilic Gram 
negative, oxidase positive curved rod exhibiting corkscrew motility.  C. jejuni is a thermo 
tolerant bacterium, with the ability to grow at temperatures between 41°C-43°C but are 
unable to grow below 30°C due to absence of cold-shock proteins (Hernandez, 1991). Its 
cephalothin resistance is applied to isolate it from cephalothin-sensitive non-
campylobacter diarrhea-causing bacteria. 
3.1.6 Pathogenesis of C. jejuni 
The infectious disease caused by Campylobacter is called campylobacteriosis. 
The gastroenteritis symptoms of C. jejuni are usually indistinguishable from other similar 
pathogens like Shigella, Yersinia, etc.  These include more commonly diarrhea, fever and 
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abdominal cramps and less frequently becteremia, septic arthritis and other extra 
intestinal symptoms (Sorvillo, 1991). The incidence of campylobacteriosis is more in 
HIV infected patients and common complications in the patients include recurrent 
infections and infections due to antibiotic resistant strains (Perlman D J, 1988). 
Campylobacteriosis leads to a much more serious disorder called the Guillain-Barré 
syndrome in about 40% of patients (Allos, 1997). Guillain-Barré syndrome is an acute 
demyelinating disorder of the central nervous system.  Only certain serotypes of C. jejuni 
are known to increase the chances of contracting this disorder. 
Poultry is considered as the main reservoir for C. jejuni, though other agents such 
as water, raw milk and direct transmission from pets has also been reported (Butzler, 
2004). Campylobacteriosis is majorly self limiting, but antibiotic resistant strains are 
more prominent in immune-compromised individuals such as HIV patients or in 
persistent infections. In such cases the usual antibiotics preferred were fluoroquinolones 
and macrolides. C. jejuni is carried in the intestine of many wild and domestic animals, 
particularly avian species, where the intestine is colonized resulting in healthy animals as 
carriers. Wildlife has long been considered an infectious reservoir for campylobacters 
because of their close association with and contaminated surface waters (Levin, 2007). 
3.1.7 Antibiotic Resistance in C. jejuni: 
It is a concern that due to use of antibiotics in food animals as therapeutic agents 
or growth promoters and since C. jejuni can be passed from animals to humans, antibiotic 
resistant C. jejuni might arise (Angulo, 2004). A significant rise in macrolide and 
fluoroquinolone resistance has been reported in human isolates of C. jejuni since the 
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1990’s (Engberg, 2001). This could have been accelerated due to widespread use of these 
antibiotics. Fortunately the prevalence of macrolide resistance in C. jejuni human isolates 
has remained low (12%) (Gibreel, 2006) while the prevalence of fluoroquinolone 
resistance has increased very high (90%) (Prats, 2000). 
3.1.8 Multi-Drug-Resistance (MDR) in C. jejuni: 
In 2002, the RND efflux pump CmeABC in C. jejuni was described. This pump 
confers resistance to several antimicrobials including fluoroquinolones, erythromycin, 
tetracycline, chloramphenicol and ampicillin, as well as detergents and dyes (Jun Lin, 
2002). To date, a number of studies have defined a contributory role of the CmeABC 
efflux system to acquired MDR (Pumbwe, 2004). CmeABC consists of three components 
as is characteristic of RND pumps, a periplasmic fusion protein (CmeA), an inner 
membrane transporter (CmeB) and an outer membrane channel protein (CmeC). The 
three components are encoded by a single polycistronic operon (cmeABC). An insertion 
mutation in the cmeB increases the susceptibility of the resistant strains to some of the 
antimicrobials, which indicates the presence of other efflux pumps (Jun Lin, 2002). 
It has been shown that the CmeABC pump acts synergistically with gyrA 
mutations to confer fluoroquinolone resistance (Luo, 2003).  In contrast to other bacteria 
where over expression of efflux pump activity is largely associated with acquired 
fluoroquinolone resistance (Kaatz, 2005), fluoroquinolone resistance in C. jejuni does not 
appear to require over expression of efflux pumps and may be mediated by single-step 
point mutations in gyrA in the presence of the constitutively expressed CmeABC pump. 
The CmeABC pump may also act independently or in synergy with the 23S rRNA 
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mutation, which is responsible for macrolide and erythromycin resistance in C. jejuni 
(Mamelli, 2005). 
Crude 60% grain alcohol goldenseal leaf extract’s activity on some of the MDR 
bacterial strains indicates that the concentration of alkaloids, specifically berberine is not 
sufficient to such levels of antimicrobial activity. The objective of this study is to analyze 
the synergistic effect of goldenseal leaf extract on the inhibition of MDR efflux pumps in 
strains of S. aureus and C. jejuni. 
 
3.2 Materials and Methods 
3.2.1 Bacterial Strains: 
The list bacterial of strains used in this study are listed in Table 3.3 along with the 
MDR pump expressed in them and the associated MDR pump family. S. aureus strains 
SA1199 (norA wild type), SA1199B (norA over expresser), RN4220 (msrA) and 
SAK2068 (mepA) and Escherichia coli strains DH10B and DH10B/pK21 (wild type 
DH10B with norA carrying plasmid pK21) were kindly provided by Dr. Glenn Kaatz 
(Wayne State University School of Medicine, Detroit, MI). S. aureus 25923 and L. 
acidophilus 53544 were obtained from ATCC, Richmond VA. All the strains were 
maintained in Mueller Hinton II (MH II) (BD-Difco) medium at 35°C under aerobic 
conditions.  
C. jejuni 81-176 (cmeABC) is a human isolate provided by Dr. Jun Lin of the 
Department of Animal Science at the University of Tennessee. These isolates were 
routinely grown in Mueller-Hinton II (MH II) broth (BD-Difco) or agar at 42°C under 
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microaerophilic conditions generated using the Anoxomat system (Mart Microbiology) in 
enclosed jars. 
 
Table 3.3: List of bacterial Strains 
 
Strain Description MDR pump family 
S. aureus SA1199 Wild type NorA MFS 
S. aureus SA1199B Over expresser NorA MFS 
S. aureus SAK2068 MepA MATE 
S. aureus RN 4220 MsrA RND 
S. aureus ATCC 25023 - - 
E. coli DH10B - - 
E. coli DH10B/pK21 Plasmid containing norA gene MFS 
C. jejuni 81-176 CmeABC RND 
 
3.2.2 Antimicrobial Assay: 
The minimum inhibitory concentrations (MICs) of different antimicrobials, 
goldenseal leaf extract and berberine sulfate were determined by using the microbroth 
assay as described by the Clinical and Laboratory Standards Institute (CLSI) for the S. 
aureus. The antimicrobial is added in serial two-fold dilutions in triplicates to round 
bottom 96 well plate and each well is seeded with 105cell/ml in MH II broth (final 
volume in each well is 200µL). The plates are incubated aerobically at 35°C for 18-24hrs 
and observed for visible growth. MIC is defined as the lowest concentration of the 
antimicrobial with no visible growth.  The assays were performed twice in triplicates. All 
the chemicals and antimicrobials were obtained from Sigma-Aldrich. Goldenseal leaf 
extract was provided by Sleepy Hollow farm, GA. 
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The minimum bactericidal concentration (MBC) is determined by taking the 
100µL from the wells that show no visible growth (≥ MIC) in the microbroth assay and 
resuspending in fresh liquid and on solid MH II media. The agar and broth is incubated 
aerobically at 35°C for 18-24hrs and observed for growth. MBC is defined as the lowest 
concentration which yielded no growth. All assays were performed twice in triplicates. 
For C. jejuni 81-176 the MICs were determined using the standard 96 well 
microtiter broth dilution method in MH II broth with an inoculum of 106cell/mL. 
Microtiter plates were incubated for 48 hrs under microaerophilic conditions at 42°C and 
observed for visual growth.  The assays were performed twice in triplicates. 
3.2.3 Synergistic assay of goldenseal leaf extract: 
The pump inhibitory activity of goldenseal leaf extract on the S. aureus strains 
was performed by a slight modification of the microbroth assay. Sub-lethal doses of the 
antimicrobial being tested and sub-lethal doses of goldenseal leaf extract are added 
together in the wells of the 96 well plates. The plates were then seeded with 105cell/mL 
in MH II broth (final volume 200µL/well). The plates were incubated aerobically at 35°C 
and observed for visible growth. The decrease in MIC is then measured in fold-decrease. 
Reserpine, a known MDR pump inhibitor, was used as a standard for MDR pump 
inhibitory activity. For the C. jejuni strains the plates were seeded with 106cell/mL in MH 
II broth. The plates were incubated for 48 hrs under microaerophilic conditions at 42°C 
and observed for visible growth. 
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3.2.4 Agar well-diffusion assay 
To demonstrate synergy between the goldenseal leaf extract and antimicrobials on 
the bacteria, a slightly modified technique of agar-well diffusion assay as described 
earlier (Schillingeur and Lucke,F, 1989). MH II agar plates were overlaid with soft agar 
seeded with 105cell/mL of the indicator bacteria (SA1199B). Wells of 1mm in diameter 
were then punched in the agar and the antimicrobial agent (goldenseal leaf extract or 
ciprofloxacin) added to them. The diameter of the zone of inhibition (ZOI) was 
measured. Synergy was demonstrated by placing the wells of ciprofloxacin and 
goldenseal leaf extract with a measured distance from the edge of ZOI of ciprofloxacin to 
the Zone of goldenseal leaf extract. A disfiguration of ZOI would indicate the 
synergy/antagonism between the two agents. 
3.2.5 Quantitative Real-Time RT-PCR: 
RNA extraction: 
The bacteria were grown overnight in MH II broth with or without sub-lethal 
doses of the EPIs (Reserpine or goldenseal leaf extract). Total RNA was then extracted 
from the bacteria using the 1-2-3 RNA extraction kit from Idaho Technologies according 
to the manufacturer’s protocols. 100µL of the cell culture was added to the bead tubes 
and the carrier RNA (RNA module) and vortexed for 5min on a Vortex Genie to lyse the 
bacteria. 450µL of the binding buffer was added to the lysate. The lysate was transferred 
avoiding the beads to a spin filter and centrifuged. The spin filter was washed twice with 
wash buffer and RNA was eluted in 50µL of the elution buffer. 
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The concentration of total RNA was determined by spectrophotometer readings at 
260nm. The purity of the RNA was confirmed by doing a ratio of absorbance at 260nm 
and 280nm and running a formaldehyde agarose gel electrophoresis.  
Real-Time RT-PCR: 
The Bio-Rad MiniOpticon Real-Time PCR Detection system was used to amplify 
cDNA following reverse transcription of the isolated total RNA so that differences in 
gene expression levels could be easily measured. Use of the Bio-Rad iScript™ One-Step 
RT-PCR Kit with SYBR Green allowed for reverse transcription and PCR to be carried 
out in one tube with fluorescence of SYBR green measured at the end of each cycle. For 
one-step RT-PCR, 25µL reaction volumes containing the followings per tube were used: 
12.5µL of 2x SYBR green master mixes, 0.5µL of 10µM forward primer, 0.5µL of 10µM 
reverse primer, 0.5µL of reverse transcriptase, 25ng RNA, and RNAase free water to 
bring the reaction volume to 25µL. Triplicate samples were run in duplicate under the 
following conditions: cDNA synthesis at 50°C for 10 minutes, RT inactivation and initial 
denaturation at 95°C for 5 minutes, denaturation for 10 seconds at 95°C and annealing 
(data collection step) for 30 seconds at 53.8°C for 35-45 cycles. The primers used in the 
gene expression assay are listed in Table 3.4. The purity of the amplicon was determined 
by doing a melt curve analysis. 
Analysis of the data generated by the RT-PCR was done by the comparative Ct 
method. The Ct values of both the control and the samples of interest were normalized to 
an appropriate endogenous housekeeping gene (16S rRNA). The threshold cycle, Ct, is 
defined as the cycle at which fluorescence crosses into the exponential phase from the 
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initial linear phase. The standard curve method was not considered as the amounts of 
RNA added to the reaction mixture were known. 
 
Table 3.4: List of primers for different strains of S. aureus used in Real time RT-PCR 
 
Strain Gene GenBank 
Accession 
No. 
Left Primer Right Primer 
S. aureus 
housekeeping  
16S 
rRNA 
L37597 tccggaattattgggcgtaa ccactttcctcttctgcactca 
SA1199, 
SA1199B 
norA M80252 agaatttatgtttgctatcggt  tttgctttttgatggcttggtg 
SAK2068 mepA AY661734 ggcaaataaaggccgtatga cagtcgcttgaagcatacca 
RN4220 msrA AF167161 agctgtgcgagatgtacgtg atgcttggtcctccctttct 
C. jejuni 
housekeeping 
16S 
rRNA 
Z29326 caacacttttaccgggtgct gccattttgcaatcctttgt 
C. jejuni 81-
176 
cmeABC AF466820 gagtgagggagaggcagatg gtttagggcgtggactacca 
 
 
3.2.6 Ethidium Bromide Uptake: 
Uptake of EtBr by the bacteria was achieved by growing the bacteria overnight in 
MH II broth. Bacteria were harvested at an OD660 of 0.7 to 0.8, washed in ice-cold MH II, 
and then resuspended in MH II to a final OD660 of 0.4. The suspension was warmed to 
37°C, and ethidium bromide  (final concentration, 20µg/mL) was added. The suspension 
was maintained at 37°C with agitation, and the fluorescence of aliquots was determined 
at frequent intervals (excitation wavelength, 530nm; emission wavelength, 600 nm). The 
effect of reserpine and goldenseal leaf extract on the uptake was measured by adding 
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them to the medium after resuspension. The final concentration of reserpine used was 
20µg/mL and that of goldenseal leaf extract was 500µg/mL. 
3.2.7 Ethidium Bromide Efflux: 
Ethidium bromide efflux studies were performed as described earlier with some 
differences (Kaatz, 2006). For ethidium bromide efflux, bacteria were grown overnight in 
MH II and diluted into the same medium as used for overnight growth, and at an OD660 of 
0.7 to 0.8. Ethidium bromide loading of bacteria was accomplished by the addition of 
ethidium bromide and reserpine (final concentrations of both being 20µg/mL). After 20 
min of incubation at room temperature, the OD660 was adjusted to 0.4 using fresh MH II 
containing ethidium bromide and reserpine or goldenseal leaf extract. Bacteria in 1 ml of 
this dilution were pelleted and then resuspended in fresh MH II without reserpine or 
ethidium bromide. Efflux of ethidium bromide was monitored by measuring the 
fluorescence of the suspension continuously (excitation and emission wavelengths, 530 
and 600 nm, respectively). The effect of reserpine (20µg/mL) and goldenseal leaf extract 
(500µg/mL) was determined on the efflux of ethidium bromide. 
3.2.8 Statistical Analysis: 
Numbers expressed as mean ± standard deviation were analyzed by Student’s T 
test. Values were considered significantly different when p values were less than 0.05. 
Notations were also made when p<0.01. 
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3.3 Results 
3.3.1 Antimicrobial Assay: 
The MICs of different antimicrobials on the bacterial strains are given in Table 
3.5 and 3.6. Table 3.5 is the results of the antimicrobial activity of ciprofloxacin, 
goldenseal leaf extract, berberine sulfate and reserpine against the NorA strains. The MIC 
of ciprofloxacin against the over expresser NorA strain SA1199B was 32-fold higher than 
that on the wild type, SA1199 while on DH10B/pK21, it was 3-fold higher than the wild 
type DH10B.  
 
Table3.5: MIC (µg/mL) of antimicrobials on the NorA pump expressing strains 
Antimicrobial SA1199 SA1199B DH10B DH10B/pK21 
Ciprofloxacin 0.25 8 0.02 0.06 
Goldenseal Leaf 
Extract 
1000 1000 1000 1000 
Berberine sulfate 125 250 >250 >250 
Reserpine > 250 >250 250 250 
 
 
The MICs of different antimicrobials on other indicator bacteria are given in 
Table 3.6. The MIC of goldenseal leaf extracts on all the S. aureus strains was 
comparable, but it exhibited a much lower MIC on the C. jejuni strain. Similarly the MIC 
of berberine on all the MDR S. aureus was high compared to that on C. jejuni. Reserpine 
showed a high MIC on all the S. aureus, E.coli and C. jejuni strains suggesting that 
reserpine has limited antimicrobial property. 
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Table 3.6: MICs (µg/mL) of different antimicrobials on the MDR strains 
Antimicrobial SA1199B SAK2068 RN4220 C. jejuni 81-176 
Ciprofloxacin 8 4 0.25 0.313 
Tetracycline 0.25 1 0.25 50 
Erythromycin 0.25 0.5 64 0.078 
Goldenseal Leaf 
Extract 
1000 500 1000 62.5 
Berberine sulfate 125 250 250 8 
Reserpine > 250 >250 >250 >100 
 
3.3.2 Synergy Studies: 
3.3.2.1 Microbroth assay: 
The synergistic activity of goldenseal and reserpine with other antimicrobials was 
evaluated against all the MDR strains. The results for synergy between ciprofloxacin and 
goldenseal leaf extract on the NorA strains are shown in Table 3.7. The sub lethal doses 
of goldenseal leaf extract evaluated were 500, 250 and 125µg/mL. There was no 
reduction in MIC of ciprofloxacin on the wild type NorA S. aureus strain SA1199. The 
MIC of ciprofloxacin on the NorA over expresser, SA1199B was reduced to 1µg/mL, 
which was an 8-fold reduction, when a sub lethal dose of 500µg/mL of goldenseal leaf 
extract was used. There was a 4-fold and 2-fold reduction in the MIC of ciprofloxacin 
observed for sub lethal doses 250µg/mL and 125µg/mL respectively. Different 
concentrations of reserpine were also assayed as controls. An 8-fold decrease in 
ciprofloxacin was observed when 20µg/mL of reserpine was used. A 4-fold and 2-fold 
decrease in ciprofloxacin was observed for 10µg/mL and 5µg/mL of reserpine 
respectively.  
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In the case of the E. coli strains the sub lethal doses of goldenseal leaf extract 
used were 500, 250 and 125µg/mL. There was a decrease in MIC of ciprofloxacin on E. 
coli DH10B/pK21 by 8-fold (0.0075µg/mL) observed for 500µg/mL of goldenseal leaf 
extract. A 4-fold and 2-fold decrease in MIC of ciprofloxacin seen with 250µg/mL and 
125µg/mL of goldenseal leaf extract was observed, respectively. No reduction was 
observed in the case of DH10B with goldenseal leaf extract. Reserpine at a concentration 
of 20µg/mL exerted a decrease of MIC of ciprofloxacin by 16-fold on the E. coli 
DH10B/pK21 and an 8 fold decrease on the DH10B strain with 20µg/mL concentration. 
An 8-fold and 4-fold reduction of MIC of ciprofloxacin on E. coli DH10B/pK21 and 4-
fold and 2-fold decrease of MIC of ciprofloxacin on DH10B was observed with 10µg/ml 
and 5µg/mL of reserpine respectively. 
 
Table 3.7: MDR pump inhibitory activity of goldenseal leaf extract on NorA strains. All 
the concentrations are in µg/mL and degree of decrease in MIC is in 
parenthesis 
 
Antimicrobial SA1199 SA1199B DH10B DH10B/pK21 
Ciprofloxacin 0.25µg/mL 8 µg/mL 0.02µg/mL 0.06µg/mL 
Goldenseal 1000µg/mL 1000µg/mL 1000µg/mL 1000µg/mL 
Ciprofloxacin + 
Goldenseal 
500µg/mL 
250µg/mL 
125µg/mL 
 
 
No change 
 
 
1µg/mL (8) 
2µg/mL (4) 
4µg/mL (2) 
 
 
No change 
 
 
0.0075µg/mL (8) 
0.015µg/mL (4) 
0.03µg/mL (2) 
Ciprofloxacin + 
Reserpine 
20µg/mL 
10µg/mL 
5µg/mL 
 
 
No change 
 
 
1µg/mL (8) 
2µg/mL (4) 
4µg/mL (2) 
 
 
0.0075µg/mL (8) 
0.015µg/mL (4) 
0.03µg/mL (2) 
 
 
0.0037µg/mL(16) 
0.0075 µg/mL (8) 
0.015µg/mL (4) 
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The synergy between other antimicrobials and goldenseal leaf extract are shown 
in Table 3.8. The sub lethal concentration of goldenseal leaf extract used for the synergy 
assay were 250µg/mL and 500µg/mL for SAK2068 and RN4220 and those of reserpine 
were 20µg/mL for both strains. The assay was also done on the ATCC 25923strain as a 
control.  
Goldenseal leaf extract exhibited a decrease in the MIC of ciprofloxacin from 4 to 
1µg/mL, a 4-fold decrease on the SAK2068, the MATE pump strain. There was also a 4-
fold reduction from 1 to 0.25µg/mL of tetracycline and 2-fold reductions from 0.5 to 
0.25µg/mL of erythromycin in synergy with goldenseal leaf extract on the SAK2068. A 
reduction of 2-fold in the MIC of ciprofloxacin and erythromycin was observed in the 
RN4220, the RND pump strain with goldenseal leaf extract. No change was observed in 
the MIC of tetracycline on RN4220 with goldenseal leaf extract. Goldenseal leaf extract 
showed a 2-fold reduction in the MIC of both, tetracycline and erythromycin on 
SA1199B, the MFS pump strain. The synergy effects of goldenseal leaf extract were 
comparable to those of reserpine on all the strains at a concentration of 20µg/mL. 
The sub lethal dose of goldenseal leaf extract for synergy studies of C. jejuni 81-
176 used was 31.25µg/mL. The MIC of ciprofloxacin against C. jejuni 81-176 was 
lowered by 16-fold from 0.313µg/mL to 0.004µg/mL. When the sub lethal dose of 
goldenseal leaf extract was lowered to 16µg/mL, an 8-fold decrease in MIC of 
ciprofloxacin was observed. Reserpine at a concentration of 20µg/mL showed a 2-fold 
decrease in MIC of ciprofloxacin against C. jejuni 81-176. Synergy of goldenseal leaf 
extract with tetracycline on C. jejuni 81-176 was not evaluated as the resistance of this 
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strain towards tetracycline id due to a different pump and not conferred by CmeABC (Jun 
Lin 2002). 
 
 
Table 3.8: MDR pump inhibitory activity of goldenseal leaf extract on MDR S. aureus 
strains. All the concentrations are in µg/mL and degree of decrease in MIC is 
in parenthesis. The sub lethal dose of goldenseal leaf extract for each stain is 
half its MIC against the strain given in parenthesis after the strain description. 
The concentration of reserpine used was 20µg/mL 
 
Antimicrobial SA1199B 
(500µg/mL) 
SAK2068 
(250µg/mL)
RN4220 
(500µg/mL) 
SA25923 
(500µg/mL) 
C.  jejuni 81-176
(31.25µg/mL) 
Goldenseal 1000µg/mL 500µg/mL 1000µg/mL 1000µg/mL 62.5µg/mL 
Ciprofloxacin 
+Goldenseal 
+Reserpine 
8µg/mL 
1(8 fold) 
1(8 fold)  
4µg/mL 
1(4 fold)  
0.5(8 fold) 
0.25µg/mL 
0.125(2 fold) 
0.125(2 fold) 
0.125µg/mL 
0.062(2 fold) 
0.062(2 fold) 
0.313µg/mL 
0.0039(16 fold) 
0.1565(2 fold) 
Tetracycline 
+Goldenseal 
+Reserpine 
0.25µg/mL 
0.125(2 fold) 
0.125(2 fold)  
1µg/mL 
0.25(4 fold)  
0.5(2 fold) 
0.25µg/mL 
0.25(none) 
0.125(2 fold) 
0.25µg/mL 
0.25(none) 
0.25(none) 
 
- 
Erythromycin 
+Goldenseal 
+Reserpine 
0.25µg/mL 
0.125(2 fold) 
0.125(2 fold)  
0.5µg/mL 
0.25(2 fold)  
0.5(none) 
64µg/mL 
32(2 fold) 
64(none) 
0.125µg/mL 
0.125(none) 
0.125(none) 
0.078µg/mL 
0.0395(2 fold) 
0.078(none) 
 
 
3.3.2.2 Agar Diffusion assay: 
The agar diffusion assay was performed on the NorA over expresser S. aureus 
strain SA1199B to demonstrate the synergy between goldenseal leaf extract and 
ciprofloxacin. The zone of inhibition of different concentrations of ciprofloxacin and 
goldenseal leaf extract was initially determined. The well containing the ciprofloxacin 
(5µg) was then surrounded by wells with different concentrations of goldenseal leaf 
extract (130µg, 260µg, 390µg and 520µg). The distance between the edges of ZOIs is 
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varied in different plates (Figure 3.2). The deformation in the ZOI of ciprofloxacin 
towards the ZOI of leaf extract indicates that there may be synergy between goldenseal 
leaf extract and ciprofloxacin. 
         
 
Figures 3.2: Agar diffusion assay of SA1199B, dist bet ZOI (i) 3mm, (ii) 5mm, iii)7.5mm 
and (iv)10mm. Wells A-D represent increasing concentrations of leaf  
surrounding the center well of ciprofloxacin 
 
 
3.3.3 Quantitative Real-Time RT-PCR: 
RNA extraction: 
After extraction, only the RNA samples that showed a 260/280 ratios falling 
between 1.9-2.1 were selected for the polymerization reaction. A formaldehyde gel 
i ii 
iv iii 
A 
A A 
A 
B B 
B B 
C C 
C C 
D 
D D 
D 
Cipro 
Cipro 
Cipro 
Cipro 
D 
D 
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electrophoresis of the samples showed a double band of RNA without any contaminants 
as is characteristic of the RNA. 
Real-Time RT-PCR: 
The comparative Ct method was employed to analyze the RT-PCR results. Ct 
refers to the threshold cycle where the fluorescence of the reporter crosses from linear 
into the exponential range.  
 
∆∆Ct = ∆Ct control – ∆Ct unknown sample 
∆Ct control = Ct housekeeping – Ct control 
Ratio of the sample to the control = 2-∆∆Ct 
 
The 2-∆∆Ct values were interpreted as follows: for values less than 1, the treatment 
caused the sample to have a 2-∆∆Ct value lower than the reference (housekeeping) 
indicating a decrease in MDR pump gene expression; values equal to 1 mean that the 
sample had the same 2-∆∆Ct as the reference and thus no change in gene expression 
between treatment and non-treatment; and values of greater than 1 indicate the treatment 
caused the sample to have a greater 2-∆∆Ct value than the reference, meaning an increase 
in MDR pump gene expression compared to untreated bacteria. 
The 2-∆∆Ct of the NorA strains SA1199 and SA1199B both treated and untreated 
with goldenseal leaf extract or reserpine are given in Table 3.9. The 2-∆∆Ct values of the 
wild type NorA SA1199 remained unchanged for both the treated and untreated samples. 
The 2-∆∆Ct of SA1199B bacteria treated with 20µg/mL reserpine was less than 1 and 
significantly different from those of the untreated bacteria (p < 0.05) indicating a gene 
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repression. At lower doses reserpine exerted an increase in the gene expression with 
significantly different from the untreated bacteria. The 2-∆∆Ct of SA1199B bacteria treated 
with goldenseal leaf extract are less than one for all the three doses, 500µg/mL, 
250µg/mL and 125µg/mL indicating a decrease in the norA gene due to treatment with 
goldenseal leaf extract. In comparison to the untreated bacteria and bacteria treated with 
reserpine, the gene repression by goldenseal was highly significant (p < 0.01).There was 
a general increase in the 2-∆∆Ct values as the dose of the goldenseal decreased. 
 
Table 3.9: 2-∆∆Ct of S. aureus NorA strains 
 
EPI 2-∆∆Ct SA1199 2-∆∆Ct SA1199B
Reserpine 
20µg/mL 
10µg/mL 
 5µg/mL 
 
1 
1 
1 
 
0.82 
1.04 
1.30 
Goldenseal leaf extract 
500µg/mL 
250µg/mL 
125µg/mL 
 
1 
1 
1 
 
0.23 
0.34 
0.53 
n=6 
 
The norA strains SA1199 and SA1199B were also treated with sub lethal doses of 
ciprofloxacin and berberine sulfate and subjected to real-time RT-PCR. No difference in 
the 2-∆∆Ct of treated and untreated samples was observed. 
The real-time RT-PCR results of other MDR strains are listed in Table 3.10. The 
concentration of goldenseal leaf extract used for SAK2068 was 250µg/mL, for RN4220 
was 500µg/mL, and for C. jejuni 81-176 was 31.25µg/mL. The concentration of reserpine 
used was 20µg/mL. The 2-∆∆Ct of the mepA of the MATE MDR strain, SAK2068 treated 
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goldenseal leaf extract* or reserpine^ were both less than 1 showing significant decrease 
in gene expression (*p < 0.01, ^p < 0.5). But the 2-∆∆Ct of SAK2068 treated with 
goldenseal was much lower than that of the SAK2068 treated with reserpine (p < 0.05). 
The results suggest that the mepA gene expression was reduced more with goldenseal leaf 
extract compared to reserpine. Similar results were observed in RN4220, the 2-∆∆Ct of 
RN4220 treated with goldenseal leaf extract was significantly lower than that of reserpine 
(p < 0.05), indicating a higher repression of msrA with goldenseal leaf extract compared 
to reserpine. The 2-∆∆Ct of bacteria treated with reserpine remained 1 indicating no change 
in gene expression while those treated with goldenseal leaf extract showed a 2-∆∆Ct of less 
than 1 indicating a gene repression exerted by goldenseal leaf extract. The level of gene 
repression by goldenseal leaf extract is shown in Figure 3.3. 
The 2-∆∆Ct of C. jejuni 81-176 treated with goldenseal leaf extract was 
significantly lower than that of the untreated bacteria   (p < 0.01) while the 2-∆∆Ct of 
reserpine was similar to those of the untreated bacteria. 
 
Table 3.10: 2-∆∆Ct values of the MDR bacteria 
 
EPI SA1199B 
(MFS) 
SAK2068 
(MATE) 
RN4220 
(RND) 
C. jejuni 81-176 
(RND) 
Leaf extract 0.23 0.19 0.27 0.184 
Reserpine 0.82 0.71 0.58 1 
n=6 
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The real-time RT-PCR was also done on RNA extracted from SAK2068, RN4220 
and C. jejuni 81-176 bacteria treated with sub lethal doses of ciprofloxacin or berberine 
sulfate. No change was observed. 
 
 
Figure 3.3: Effect of goldenseal on the gene expression of MDR pump genes 
  n=6, *p<0.01, ^p<0.05 
 
 
 
3.3.4 Ethidium Bromide Uptake: 
The Ethidium Bromide (EtBr) uptake of bacteria without any EPI is shown in the 
chart in Figure 3.4: The wild type NorA strain showed a steady increase in fluorescence 
indicating accumulation of EtBr in the bacteria, which normalized after a time. All the 
other MDR bacteria showed an increase in initial EtBr uptake and after an interval there 
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is a decrease in fluorescence. This might indicate the efflux of EtBr by the the MDR 
efflux pumps. 
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Figure 3.4: Ethidium bromide uptake of S. aureus strains 
               n=6 
 
The effect of reserpine and goldenseal leaf extract on the bacteria is shown in the 
charts in Figures 3.5 and 3.6. Compared to the absence of any EPI, reserpine significantly 
showed an increase in the fluorescence in all the MDR bacteria (p <0.05) which after a 
time still increases but at a very slow rate. This was true in the case of SA1199 wild type 
strains also, which also shows a sharp accumulation initially and then a gradual slow 
increase in fluorescence. 
The effect of goldenseal leaf extract is shown in the chart in Figure 3.6. 
Goldenseal leaf extract showed an opposite effect of reserpine. The goldenseal leaf 
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extract did not show any effect on the EtBr uptake in the wild type SA1199, which 
showed a similar line as in with just the SA1199 bacteria without EPIs. Similar was the 
case with the MDR bacterial strains on which the goldenseal leaf extract did not show an 
increase in the EtBr accumulation. One deviation observed was the sudden sharp increase 
and decrease in fluorescence in the case of the MsrA pump RN4220. 
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Figure 3.5: Effect of reserpine on EtBr uptake of S. aureus strains, reserpine was added 
10 min after EtBr  exposure. n=6 
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Figure 3.6: Effect of goldenseal leaf extract on EtBr uptake of S. aureus strains, extract 
was added 10 min after exposure to EtBr, n=6 
 
 
 
The EtBr uptake by C. jejuni 82-176 bacteria is shown in the chart in Figure 3.7. 
The EPIs were added 10 min after the bacteria had been exposed to EtBr. All the three 
samples showed a similar increase in fluorescence initially. After 10 min the fluorescence 
of the untreated C. jejuni 81-176 stopped increasing and decreased slightly after 50 min 
and leveled again. The bacteria to which reserpine was added continued to show a 
significant increase (p < 0.05) in comparison to the bacteria without EPIs in fluorescence 
before falling slightly at 50 min. The bacteria treated with goldenseal leaf extract 
however showed a significant decrease in the fluorescence right after it was added and 
continued decreasing before leveling off at 40 min in comparison to the bacteria without 
any EPI. 
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Figure 3.7: Effect of goldenseal leaf extract and reserpine on the EtBr uptake of C. jejuni 
81-176 bacteria n=6  
 
3.3.5 Ethidium Bromide efflux: 
For the EtBr efflux studies the bacteria had to be first primed with an EPI such as 
reserpine which would enable the bacteria to accumulate EtBr without effluxing it out. 
These bacteria were then washed and resuspended in fresh medium without any EPI. The 
efflux of EtBr from the bacteria was then observed along with the effect of reserpine 
(20µg/mL) and goldenseal leaf extract (500µg/mL) on the efflux of ethidium bromide 
from the bacteria. 
 
55 
 
Ethidium bromide efflux in S. aureus strains
0 5 10 15 20 25
0
50
100
150
SA1199
SA1199B + goldenseal
SA1199B
SA1199 + reserpine
Time in min
Fl
uo
re
sc
en
ce
 in
 a
rb
itr
ar
y 
un
its
 
Figure 3.8: Ebro efflux of strains SA1199 and SA1199B in the presence and absence of 
MDR pump inhibitors n=6 
 
 
Proserpine inhibited the efflux of Ebro as indicated by no decrease in fluorescence 
in the SA1199B (Figure 3.8). While goldenseal leaf extract did not inhibit the Ebro 
efflux, as the fluorescence decreased gradually with time. There was no effect of 
reserpine or goldenseal leaf extract on the efflux of EtBr from the wild type SA1199 
bacteria. 
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3.4 Discussion 
Goldenseal leaf extract, though limited in its antimicrobial activity, potentates the 
activity of other antimicrobials. There was a higher EPI activity of goldenseal leaf extract 
observed on the SA1199B (NorA- MFS pump super family) and the SAK2068 (MepA-
MATE pump super family) with more than 4-fold decrease in the MIC of ciprofloxacin 
seen. Limited activity was seen against the MsrA pump (RND pump super family) 
carrying RN4220 with only a 2-fold decrease in the MIC of macrolide tested 
(erythromycin).  
Goldenseal leaf extract increases the susceptibility of the CmeABC pump 
carrying strain of C. jejuni: 81-176 towards ciprofloxacin and erythromycin, by 
repressing the gene encoding the pump. Goldenseal leaf extract decreases the MIC of 
ciprofloxacin on C. jejuni by 16 folds.  
The MDR pump inhibitory activity of n leaf extract at half MIC was comparable 
to that of reserpine. Reserpine has been demonstrated by other groups as an inhibitor of 
various MDR pumps including the P-glycoprotein, NorA and MepA (Kaatz, 2006). 
Reserpine at the concentrations required to obtain the desired MDR pump inhibitory 
activity has been cited to have some side effects such as neurotoxic effects (Moudgal, 
2003). The use of goldenseal leaf extract as an EPI could overcome this problem. 
Currently many groups are trying to develop EPIs to market as combination therapies. 
There are many ways an EPI could act on the MDR pump, three main possibilities 
are: reduction in mRNA production (gene repression), interference in the protein pump 
function, and/or changing the biochemical structure of the protein pump. The real-time 
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RT-PCR and ethidium bromide studies were conducted to analyze this property. 
Reserpine reduces NorA mediated EtBr efflux as is demonstrated by the EtBr studies. In 
similar assay the goldenseal leaf extract did not show any effect on the EtBr efflux by the 
NorA pump.  
The mRNA production was determined after incubating the bacteria with sub 
lethal doses of goldenseal leaf extract with the MDR bacteria. There was a decrease in the 
mdr genes of all the MDR bacteria and C. jejuni. This indicates that there was gene 
repression seen when the bacteria were exposed to goldenseal leaf extract. Reserpine 
showed an opposite effect on the MDR bacteria. While it reduces the efflux pump 
mediated EtBr efflux, there was no significant change in gene expression of the mdr 
genes.  
The conclusion that can be derived from these observations is that goldenseal 
increases the susceptibility of the MDR bacteria to different antimicrobials by decreasing 
the mRNA production of the MDR pump genes and does not affect the pump efflux. 
There maybe one or more components in the crude goldenseal leaf extract which causes 
these effects on the bacteria.  
Specifically in the case of the MsrA pump of S. aureus, belonging to the RND 
family, until recently no known EPI was available, in 2007, diterpene totaral has been 
shown to inhibit the pump (Kaatz, 2007). Goldenseal exhibited an inhibition of this pump 
as indicated by the result of synergy studies. Further evaluation of goldenseal leaf extract 
on the Gram- negative bacteria C. jejuni that carries the MDR pump CmeABC and MsrA 
pump of S. aureus, both of which belong to the RND family determine that goldenseal 
58 
 
leaf extract has a higher synergistic activity on the CmeABC pump when compared to the 
MsrA pump. A more thorough analysis is required to understand the variations in the 
effect of goldenseal on pumps belonging to the same family in both Gram positive and 
Gram negative bacteria. 
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Chapter 4 
 
 
Separation and Identification of Goldenseal Leaf Extract Constituents 
 
 
 
4.1 Introduction 
Many active compounds have been previously reported in goldenseal including 
alkaloids berberine, hydrastine and canadine (Figure 1.6), secondary metabolites such as 
protoanemonin and glycosides, berberastine, meconin, chlorogenic acid, phytosterins, 
and resins, albumin, starch, fatty acids, sugars, lignins, and volatile oils. (Van Berkel, 
2007). Berberine extracts and salts have been demonstrated to exhibit growth inhibition 
of intestinal parasites like Giardia lamblia, Entamoeba histolytica, Trichomonas 
vaginalis, (Kaneda, 1990) and  Leishmania donovani, (Abidi, 2005) with crude extracts 
being more effective than berberine salts (Kong, 2004).  
Canadine is known for its sedative and muscle relaxant properties. The third 
alkaloid hydrastine is a valuable drug for treatment of skin diseases, both taken internally 
and used as topical applications. It is especially useful as a stomachic tonic, and as a 
hepatic stimulant in cutaneous infections. It exhibits better activity when used as a topical 
application than taken internally (Beckstrom-Sternberg, 1997).  
Two new C-methyl flavonoids, 6,8-di-C-methylluteolin 7-methyl ether and 6-C-
methylluteolin 7-methyl ether have been isolated and have  activity against oral 
pathogens such as Streptococcus mutans and Fusobacterium nucleatum (Hwang, 2003). 
Quinic acid feruloyl esters have also been identified and their activity against 
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Mycobacterium tuberculosis was evaluated but showed no significant effect (Gentry, 
1999). 
The objective of this study was to isolate and identify the constituent(s) in 
goldenseal leaf extract which may be associated with the MDR efflux pump inhibitory 
activities previously observed. 
 
4.2 Materials and Methods 
4.2.1 Goldenseal Leaf Extract Sample 
The goldenseal leaf extract was supplied by the Sleepy Hollow Farm and it was a 
60% grain alcohol extract with a dry weight of 13mg/mL. A volume of 1mL of the 
goldenseal leaf extract was concentrated in using a Speed-Vac and then its final 
concentration adjusted to 130mg/mL with 60% grain alcohol.  
4.2.2 Bacterial Strains 
The S. aureus strains, SA1199B, SAK2068 and RN4220 were used to test for 
growth inhibition using thin-layer chromatography (TLC) bioautography were provided 
by Dr. Glen Kaatz (Wayne State University School of Medicine, Detroit, MI). The 
bacteria were maintained in Mueller Hinton II (MH II) (BD-Difco) medium at 35°C 
under aerobic conditions.  
4.2.3 Thin Layer Chromatography (TLC) 
Preparative thin layer silica gel based glass plates (size 20cm × 20cm) (EMD 
Chemicals) incorporated with a fluorescent indicator F254 were used for the separation of 
goldenseal leaf extract constituents. Different amounts of the concentrated goldenseal 
61 
 
leaf extract (1.3mg, 2.6mg and 3.9mg) and berberine sulfate (0.067mg, 0.134mg and 
0.201mg) were spotted onto the TLC plates and developed in ascending phase. Four 
different solvent systems, i.e. ethyl acetate:methanol (1:1), acetone:ethanol (1:1), 
butanol:acetic acid/water (7:1:2) and chloroform:methanol (9:1) were tested to determine 
the best solvent system for separation. The TLC chamber was filled with the solvent 
mixture, lined with filter paper and allowed to saturate.  Spotted TLC plates were then 
placed vertically in the chamber and allowed to develop for 15cm. The plates were then 
removed and allowed to dry and observed under the fluorescent light immediately. All 
the solvents were obtained from OmniSolv EMD Chemicals. 
 
4.2.4 Bioautographic Studies: 
To test the antimicrobial activity of various constituents separated on the TLC 
plates, TLC bioautographic assay was done as described previously (Choma, 2005) with 
slight modifications. The developed TLC plates were dried in the 37°C oven for 4 hours. 
The plates were then sprayed with 108cell/mL of the bacteria to be tested, with or without 
a sub lethal dose of ciprofloxacin. The plates were then incubated for overnight at 35°C 
in a humidified box to prevent the plates from drying. The incubated plates were then 
sprayed with 2mg/mL triphenyl tetrazolium chloride (TTC) salt solution and incubated at 
37°C for 4hrs and TTC was used to facilitate the detection of the zone of inhibition (ZOI) 
of the bacteria. 
4.2.5 Sample Preparation For Analysis: 
Five concentrated goldenseal samples (13mg each) were spotted onto the TLC 
plate and developed in chloroform/methanol (9:1) solvent system. Identical bands among 
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the 5 lanes on the developed TLC silica gel were scraped off, resuspended in the same 
solvent mixture, and pooled together. Each pooled sample was then vortexed and filtered 
through 1.2 followed by 0.2µ PTFE syringe filters. 
4.2.6 Gas Chromatography/Mass Spectrometry (GC/MS) 
An Agilent 7890 GC system interfaced with an Agilent 5975 mass selective 
detector was used (Agilent Technologies, Newark DE). GC/MS analysis of each of the 
pooled sample was conducted by injecting 2µL HP-5 MS column (30m x 250µm, 
0.25µm). Gas chromatographic operating conditions were as follows: split injection 
mode; injector temperature, 250 °C oven temperature, 80°C for 6 min, then programmed 
at 5°C/min to 130 °C, and held for 5 min and then 15°C/min to 300°C. The carrier gas 
was helium set at a constant flow of 0.4mL/min. The mass spectrometer was turned on at 
4min. The mass range scanned was 35-500 amu and the source temperature, 250 °C. 
Mass spectral data were processed using the Agilent GC/MSD ChemStation software. 
4.2.7 Liquid Chromatography/Mass Spectrometry (LC/MS) 
LC/MS analysis was performed on an Agilent 6100 series LC/MS in which a 
quadruple mass spectrometer was coupled to an Agilent 1200 HPLC (Agilent 
Technologies, Newark DE) that consisted of a G1329A high performance autosampler 
(HP-ALS-SL), a G1312A binary pump (BIN-SL), a G1379B vacuum degasser, a 
G1316A thermostatted column compartment (TCC-SL) and a G1314B variable 
wavelength detector (VWD-SL). The quadruple mass spectrometer was operated with an 
atmospheric pressure electrospray ionization (API-ES) source in positive mode. The flow 
rate of HPLC was maintained at 1 mL/min through a Kromasil RP C18 column ( column 
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size of 150mm × 4.6mm p 5µm particle size, Alltech Associates, Inc. Deerfield, IL). The 
mobile phase is an isocratic elution consisted of methanol and water (v/v=87:13) 
containing 0.1% H3PO4. Mass spectra were recorded within the m/z range of 100-1000. 
The dry gas flow for the MS was 13.0 L/min, the nebulizer pressure was 30 psi, dry gas 
temperature was 350°C, and the Vcap voltage was 3500 V. Data was acquired from the 
and processed by the Agilent LC/MSD ChemStation software. 
 
4.3 Results 
4.3.1 TLC: 
Four different solvent systems were evaluated for the separation: 
chloroform/methanol (9:1), butanol:acetic acid:water (7:1:2), acetone:ethanol (1:1) and 
ethyl acetate:methanol (1:1) (Figure 4.1). Better separation was achieved with 
chloroform/methanol with 10 bands resolved on the TLC plate. Separation was also good 
on the butanol/acetic/acid/water plate, while the other two solvent systems did not yield 
satisfactory separation.  
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Figure 4.1: TLC separation of goldenseal leaf extract using (a) ethyl acetate:methanol,  
       (b) acetone:ethanol, (c) butanol:acetic acid/water and (d) (c) chloroform: 
       methanol 
       * band of berberine  
                   # hydrastine (identified by GC/MS) 
 
 
Separation of goldenseal leaf extract yielded in the appearance of 10 bands with 
the chloroform:methanol (9:1) solvent system. The third band (Rf =0.4) was the berberine 
alkaloid and the seventh band (Rf =0.76) was identified by GC/MS analysis as the 
hydrastine alkaloid. 
4.3.2 TLC Bioautography: 
Triphenyl tetrazolium chloride (TTC) salt is a dehydrogenase sensitive 
compound. The dehydrogenases produced by live cells convert TTC to a brightly colored 
formazon. This property helps in observing the clear zone-of-inhibition which resulted 
from cell death due to antimicrobial activity by individual constituents present in 
a b c d
*
*
*
*
#
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goldenseal leaf extract by themselves or in synergy with sub lethal dose of ciprofloxacin 
(Figure 4.2). 
 
 
Figure 4.2: Zone of inhibition (ZOI) of a) goldenseal leaf extract, (b) berberine sulfate  
        and (c) ciprofloxacin prior to separation 
 
Of all the solvent systems, bacteria were able to grow only on the TLC plates 
developed in chloroform:methanol solvent system. Identification of active compounds in 
goldenseal leaf extract was not possible on TLC plates developed in the other solvent 
systems as the bacteria sprayed on these plates did not survive.  
Goldenseal leaf extract showed a ZOI before separation by chloroform/methanol 
but no zones of inhibition were observed after separation with chloroform/methanol 
(Figure 4.2). Berberine sulfate and ciprofloxacin gave rise to zones of inhibition before 
and after development of the TLC plates. TLC plates of goldenseal leaf extract (1.3mg, 
2.6mg and 3.9mg) developed in chloroform:methanol then sprayed with bacterial 
suspension of NorA over expresser SA1199B, seeded with sub lethal dose of 
ciprofloxacin (1µg/mL, one eighth of its MIC) gave rise to 4 ZOIs. These ZOIs were not 
caused by the band where berberine typically is located at but other components (Figure 
4.3). This was confirmed by developing TLC plates spotted with an equivalent 
a 
b c
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concentration of berberine sulfate (0.067mg, 0.134mg and 0.201mg) as to that of the 
goldenseal leaf extract. 
 
 
Figure 4.3: TLC bioautographic studies of SA1199B: 
• Plate 1:SA1199B sprayed on developed TLC plate spotted with goldenseal 
leaf extract 
• Plate 2: SA1199B + sub lethal dose of ciprofloxacin on developed TLC 
plate spotted with goldenseal leaf extract 
• Plate 3: SA1199B sprayed on developed TLC plate spotted with beberine 
sulfate in equivalent concentration  to that in the leaf extract 
spotted in earlier plates 
• Plate 4: SA1199B + sub lethal dose of ciprofloxacin sprayed on developed 
TLC plate spotted with beberine sulfate in equivalent 
concentration to that in the leaf extract spotted in earlier plates 
* Band of berberine 
 
 
** * *
1 2 3 4
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ZOIs were also seen on bioautographic TLC plates with other MDR bacteria. 
Table 4.1 lists the retention factors (Rf) of the bands around which zones of inhibition 
were observed. The number of zones of inhibition was different for different bacteria. 
 
 
Table 4.1: ZOIs on TLC plates sprayed with indicator 
bacteria seeded with sub lethal dose of 
ciprofloxacin 
 
Band Rf ZOI on SA1199B ZOI on SAK2068
1 0.13 Yes Yes 
2 0.33 Yes No 
3 0.41 Yes No 
4 0.58 Yes Yes 
5 0.66 Yes Yes 
 
 
 
 
68 
 
 
Figure 4.4: Number of ZOIs on SA1199B + sub lethal dose of ciprofloxacin sprayed on 
developed TLC plate spotted with goldenseal leaf extract and developed in 
chloroform:methanol (9:1) 
 
There were 3 ZOIs seen on TLC plates for SAK2068 (Figure 4.6) when sprayed 
with bacterial suspension seeded with sub lethal dose of ciprofloxacin. No ZOIs were 
observed when the developed TLC plate was sprayed with RN4220 seeded with sub 
lethal dose of ciprofloxacin. 
 
 
Berberine
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Figure 4.5: TLC bioautographic studies of SAK2068: 
• Plate 1: SAK2068 sprayed on developed TLC plate spotted with 
goldenseal leaf extract 
• Plate 2: SAK2068+ sub lethal dose of ciprofloxacin on developed TLC 
plate spotted with goldenseal leaf extract 
 
 
4.3.3 GC/MS: 
The five active bands (Figure 4.4) isolated from the TLC plate developed in 
chloroform:methanol were analyzed in GC/MS. The presence of hydrastine (band 7 on 
TLC) in the goldenseal leaf extract was confirmed by the GC/MS. No other compounds 
were detected by GC/MS possibly due to lack of volatility of the compounds. 
4.3.4 LC/MS: 
In the spectra of LC/MS analysis of bands causing ZOI on the TLC plate, more 
than one compound appeared to be present in the samples. The list of possible 
compounds associated with ZOI bands, with their retention time, is given in Table 4.2. 
 
 
* *
1 2
ZOI-1 
Berberine 
ZOI-4 
ZOI-5 
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Table 4.2: List of compounds predicted by LC/MS data 
 
 
 
 
 
ZOI-1 
Peak Retention 
time 
List of possible compounds CAS 
number 
1 5.349 
min 
1. Oxayohimban-16-carboxylic acid, 
16,17-didehydro-19-methyl-, methyl 
ester, (19α)-(ajmalicine)  
2. 2H-1-Benzopyran-2-one, 7-hydroxy-6-
methoxy-3-[(2-oxo-2H-1-benzopyran-
7-yl)oxy]- (coumarin) 
483-04-5 
 
2034-69-
7 
2 6.576 
min 
1. 2,6-Pyridinedicarboxylic acid, 4-[2-
(2,3-dihydro-1H-indol-1-yl)ethenyl]-, 
dimethyl ester, (E)- (9CI) (betalain) 
94272-
40-9 
 
 
 
ZOI-2 
1 5.929 
min 
1. (E)-Secocholest-1(10)-EN-3,5- Dione 
2. Tricyclo[10.2.2.25,8]octadeca-
5,7,12,14,15,17-hexaene-6,17-
diacetonitrile, 13,15-
bis(dimethylamino)-, stereoisomer  
- 
87387-
04-0 
2 9.173 
min 
1. Estra-1,3,5(10)-trien-17-one, 3,11-
bis[(trimethylsilyl)oxy]-, (11β)- (9CI)  
2. 5, 10-dihexyl-5, 10-dihydroindolo[3, 2-
B] 
3. 1(3H)-Isobenzofuranone, 3,3'-(4,6-
dimethoxy-1,3-phenylene)bis[3-
methyl- (9CI)  
4. Dimethyl 2-(1’, 4’-dimethoxy-9’, 10’ -
dioxo 
69688-
38-6 
- 
64042-
52-0 
- 
ZOI-3 0 - No peaks were observed in the third band 
during LC/MS analysis 
- 
ZOI-4 1 9.161 
min 
1. 2-[3-methyl-6-(1-methylethenyl)-2-
cyclohexan 
- 
ZOI-5 1 9.234 
min 
1. 13-oxa-16-aza-
hexacyclo[9.6.3.2.[4.7]0[1 
- 
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4.4 Discussion 
The TLC bioautographic studies clearly indicated that one or more constituents in 
goldenseal leaf extract act in synergy with ciprofloxacin in increasing its potency towards 
MDR bacteria. The MDR strains SA1199B (NorA) and SAK2068 (MepA) showed ZOIs 
on the developed TLC plates spotted with goldenseal leaf extract, then sprayed with sub 
lethal dose of ciprofloxacin and indicator bacteria. No ZOI was exhibited by the RN4220 
strain which might be due to the fact that the concentration of the potential EPI might not 
be enough or the synergistic activity is due to more than one component. 
 None of these constituents which caused the ZOIs could be detected by GC/MS, 
possibly due to the volatility of the compounds, as they might be non-volatile and many 
of the active components of goldenseal cannot be analyzed using GC/MS. Berberine is 
one such example which cannot be detected by GC/MC (Weber H, 2003). Further 
analysis involving derivitization of these compounds is involved in order to assay using 
GC/MS. 
 The samples detected by LCMS had one or more peaks typical to the presence of 
one or more compounds. Most notable of these is the alkaloid ajmalicine, produced by 
many other plants such as Rauwolfia serpentina (Bein, 1956). One interesting fact to be 
noted is that reserpine is also an alkaloid produced by the Rauwolfia sps (Saxena, 2009). 
The anti tumor properties of ajmalicine has been evaluated by one group (Xiuwei, 2009). 
Another compound, estra, is known to be used as a contraceptive. Coumarin another 
compound detected by LC/MS, has been reported for its anticoagulatory properties and 
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its potential application in medicine (Wang, 2006). Another compound betalain, used as a 
red colored dye, is also being investigated for its anti-tumor activity (Zakharova, 2000).  
 The other compounds which could not be identified by LC/MS need to be further 
analyzed as they could be derivatives of some known compounds and their activity 
assayed. 
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Conclusion 
 
 
 
Multi-drug-resistance due to efflux pumps in bacteria has become an important 
problem that needs to be addressed urgently. The study of efflux pump inhibitors 
suggests new applications in the treatment of multi-drug-resistant bacterial infections. 
Several efflux pump inhibitors have been identified, some are being investigated on 
clinical trials and some cannot be used due to harmful side effects. The identification and 
development of safe and effective inhibitors of bacterial efflux pumps is needed. Plants 
can be excellent sources for efflux pump inhibitors and this source needs to be 
investigated thoroughly for the identification of potential efflux pump inhibitors. 
Alternative therapy for the treatment of infections caused by different micro organisms 
has been applied since ancient times, especially using phytochemicals. Goldenseal is one 
such phytochemical which has been used for different ailments. 
The goal of this project is to evaluate the antimicrobial activity and possible 
multi-drug efflux pump inhibitory effects of crude grain alcohol goldenseal leaf extract. 
The antimicrobial properties of the goldenseal leaf extract were determined. It is evident 
that one or more constituents in the extract work in synergy to produce the antimicrobial 
effect. It is also evident that L. acidophilus, a human intestinal beneficial bacterium, 
although equally susceptible to berberine, ciprofloxacin, and reserpine when compared to 
the pathogens evaluated, it is much less susceptible to goldenseal. This is favorable since 
the impacts on the beneficial microflora exerted by therapeutic agents should be 
minimized. The efflux pump inhibitory activities of goldenseal leaf extract were 
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evaluated with results indicating that goldenseal leaf extract increases the susceptibility 
of the MDR bacteria towards various antimicrobials. Some of these bacteria overexpress 
MDR pumps which belong to different MDR pump superfamilies. Goldenseal leaf extract 
effectively decreased the MIC of ciprofloxacin against the pumps NorA (MFS) and 
MepA (MATE) in S. aureus (≥ 4 folds) and CmeABC (RND) in C. jejuni (16 folds). 
Synergy studies of the goldenseal leaf extract clearly indicate that it represses the 
genes encoding for these MDR efflux pumps, which is in contrast to that of reserpine. 
Reserpine shows a very limited or no gene repression of these MDR pumps. These 
synergy studies also indicate that reserpine inhibits the protein MDR pump by interfering 
with its function and goldenseal leaf extract does not show this property. This property of 
goldenseal leaf extract has to be further evaluated as it is the balanced overall effects of 
its constituents rather than the effects of individual constituent are being observed. 
Subsequent isolation, and evaluation of purified individual constituent is required for 
insight into the mechanism of action in order to optimize the use of such agents to 
overcome multi-drug resistance.                                                                                                                          
The resistance of C. jejuni to multiple drugs is not due to its overexpression of 
CmeABC pumps (Mamelli, 2005) but it may work in synergy with other mutations to 
confer the resistance. Goldenseal leaf extract seems to overcome all these factors since it 
effectively decreases the MIC of ciprofloxacin and erythromycin by at least 2 folds. It 
also decreases the MIC of erythromycin in the MsrA pump (RND) carrying strain of S. 
aureus by at least 2 folds. As previously mentioned, no EPI that inhibits the MsrA pump 
efflux has been identified until recently (Kaatz, 2007). Kaatz et al have identified a 
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compound diterpene totarol which they have shown to inhibit MsrA efflux. Goldenseal 
leaf extract shows an efflux pump inhibitory activity against both the RND pumps used in 
this study, i.e., MsrA of S. aureus and CmeABC of C. jejuni. The positive control used 
for the efflux pump inhibitory activity, reserpine did not inhibit either of these pumps.   
Lastly, an initial separation and identification of the constituent(s) responsible for 
this behavior was attempted. The TLC bioautographic studies indicated more than one 
band that showed a possible anti efflux pump activity against the NorA (MFS) and MepA 
(MATE) pump carrying strains of S. aureus. No active bands could be isolated with the 
MsrA pump strain of S. aureus, indicating that one or more constituents maybe acting 
together to show the inhibition. 
Further studies are needed to purify, identify, and characterize these specific 
constituents. The evaluation and characterization of these individual constituents could 
lead to the development of combination therapies that combine goldenseal constituents 
and therapeutic agents with improved antimicrobial qualities, i.e., increased potency with 
reduced side effects, for use in clinical trials to treat multi-drug resistant bacterial 
infections. 
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